The hypolipidemic effect of some lesser-known Chinese edible and medicinal mushrooms. by Yeung, Ming. & Chinese University of Hong Kong Graduate School. Division of Biology.
THE HYPOLIPIDEMIC EFFECT OF SOME 
LESSER-KNOWN CHINESE EDIBLE AND 
MEDICINAL MUSHROOMS 
YEUNG Ming 
A Thesis Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Master of Philosophy 
in 
Biology 
©The Chinese University of Hong Kong 
August 2003 
The Chinese University of Hong Kong holds the copyright of this thesis. Any 
person(s) intending to use a part or whole of the materials in the thesis in a proposed 
publication must seek copyright release from the Dean of the Graduate School. 
M 3 0 B _ )i| 
跃 一“"UNIVERSlfT— 
c^J^ LIBRARY SYSTEMy^ ^ 
THESIS COMMITTEE: 
Professor Cheung Chi Keung Peter (Supervisor) 
Professor Wong Yum Shing 
Professor Chung Hau Yin Anthony 
Professor Ma Ching Yung (External Examiner) 
i 
ANKNOWLEDGEMENTS 
Firstly, I would like to show my greatest appreciation to my supervisor 
Professor Peter C. K. Cheung, for his patience, sincere guidance, and constructive 
suggestions through out the whole period of my research. 
Secondly, I deeply thank Professor Y. S. Wong and Professor Anthony H. Y. 
Chung for their valuable advice, enthusiastic encouragement and precious time as the 
members of my thesis committee. 
Thirdly, I am grateful for Professor C. Y. Ma, for his valuable comments and 
willingness to be my external examiner. 
The technical support from Mr. Li Chi Chiu, is also treasured. Without his warm 
assistance, this research progress could not go as smoothly as by now. 
I also highly appreciate Mr. Zhang Ze Sheng, who spent lots of time to advise me 
in gas chromatography analysis and enzyme activity determination. 
Furthermore, I would like to thank Mr. Lam Lik Wang, Mr. Xu Yan Tong and 
Miss Cheung Lai Ming for their unselfish help in animal handling. 
Finally, I sincerely thank my parents, sister, friends, and all the kindhearted lab 
mates, for their understanding and encouragement to help me pass the hardest time 
during this two-year research career. 
ii 
ABSTRACT 
Nowadays as dietary intake of cholesterol and saturated fat in human is 
increasing and the evidence of its positive correlation with coronary heart disease 
(CHD) is emerging, the hypolipidemic effect of natural products as "functional food" 
has attracted much attention. Among them, some types of edible mushrooms—such as 
Lentinus edodes and Pleurotus ostreatus have been proved to show significant 
hypocholesterolemic effect. 
The aim of this research is on the investigation of lipid (L)- and cholesterol 
(C)-lowering effect in some lesser-known Chinese edible and medicinal mushrooms 
that have potential commercial value. 
Firstly, a preliminary screening of eleven mushrooms was conducted by using 
the AIN-93M diet formula with a slight modification (addition of 5% dry mushroom 
powders and 2% C which replaced the com starch portion). The semi-synthetic high C 
diet was fed male Sprague-Dawley rats for 28 days, and the serum lipid profiles, 
hepatic lipid profiles, fecal neutral sterol and bile acid excretion of the animals were 
analyzed. Among all the mushrooms tested, Agrocybe aegerita (Brig) Sing (AA) 
significantly (P < 0.05) reduced the levels of serum total C (TC), triglyceride (TG), 
atherogenic index, hepatic total L (TL) and hepatic TC by 38.14%, 29.21%, 87.83%, 
31.99%, and 38.49%, respectively, when compared to the blank control group 
(without 5% mushroom). AA mushroom contained 24.11% crude protein, 30.48% 
total dietary fiber, 2.54% fat, 6.97% ash, 7.00% moisture and 28.90% carbohydrate 
(calculated by difference). 
Secondly, a dose-response relationship on the hypolipidemic activity of AA was 
investigated. Three different amounts (5%, 10% and 20%) of dry AA powder were 
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added to the above semi-synthetic high C diet. Our results showed that there was a 
significant positive linear correlation between the percentage of mushroom 
supplement in the diets and the HDL/TC ratio (R=0.987; P<0.001), which suggested a 
dose-response relationship between AA and anti-atherotic ability. 
Thirdly, a fractionation of the hypolipidemic active components of AA was 
attempted by extraction using hot water and pure ethanol, followed by oral 
administration of these extracts to rats fed a high C diet. The results showed a trend of 
serum and hepatic lipid-lowering effect in the hot water extract in a short period of 3 
weeks' time. 
Finally, a long-term hypolipidemic effect of AA supplementation was 
investigated by a 12-week feeding experiment in normolipic rats. AA supplemented 
diet group showed a continuously inhibition effect of cholesterol accumulation in 
serum and liver, but had no significant effect to serum TG level. Moreover, by ['"^C 
labeled tracing, two rate-limiting hepatic enzymes affecting C metabolism were 
studied: 1) activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase in A A supplemented group was decreased by 37.6% as compared to the 
control group, which might lead to the reduction of endogenous C synthesis; 2) 
activity of cholesterol-7-alpha-hydroxylase (CYP7A), which catalyzes the 
degradation of C to bile acids, was significantly increased in the AA supplemented 
group by more than twofold than the control group, suggesting an acceleration of the 
catabolic rate of C had occurred. Also, levels of fecal neutral sterol excretion were 
significantly increased in the A A diet group compared to the control group. All of the 
above results might account at least partially for the mechanisms of the hypolipidimic 
effect in AA mushroom. 
The results obtained so far will provide useful knowledge on the understanding 
of the hypolipidemic effect in some Chinese mushrooms that relate to the application 
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of edible fungi as functional food, especially for AA. In an effort to discover more of 
its beneficial health effects, further investigations on the active chemical component(s) 
and the detailed pharmacological mechanisms would be required to develop these 



















5 % ’ 10%和20%三種不同劑量的茶薪薛乾粉。實驗結果表明，食物中薛類添加 
物的百分比與高密度脂蛋白膽固醇對血清總膽固醇比率之間存在著明顯的線性 





















TABLE OF CONTENTS 
Pages 
THESIS COMMITTEE i 
ACKNOWLEDGEMENTS ii 
ABSTRACT (ENGLISH) i i i�v 
ABSTRACT (CHINESE) v i�vi i 
TABLE OF CONTENTS viii�xiii 
LIST OF TABLES xiv�xv 
LIST OF FIGURES xvi�xviii 
LIST OF ABBREVIATIONS xix~xx 
CHAPTER ONE: INTRODUCTION.... 1 
1.1 Different lipoproteins and their functions 1 
1.1.1 Chylomicrons 4 
1.1.2 VLDL." 4 
1 丄3 LDL 4 
1.1.4 HDL 5 
1.2 Risk factors of coronary heart disease (CHD) 5 
1.2.1 Background information of CHD 6 
1.2.2 Relationship between serum total cholesterol (TC), Low-density lipoprotein 
(LDL) cholesterol and CHD 7 
1.2.3 High-density lipoprotein (HDL) cholesterol and CHD 8 
1.2.4 Triglyceride and CHD 9 
1.3 Cholesterol homeostasis 10 
1.3.1 Roles of HMG-CoA reductase in cholesterol biosynthesis 13 
1.3.2 Roles of cholesterol 7a-hydroxylase (CYP7A) in cholesterol catabolism.....15 
viii 
1.3.3 Effects of Short-Chain Fatty Acid (SCFA) 17 
1.3.4 Related hormone 18 
1.4 Possible mechanisms of hypolipidemic agents 19 
1.4.1 Hypolipidemic functional foods 20 
1.4.2 Pharmacological drugs 26 
1.5 Edible and medicinal mushrooms 28 
1.5.1 General introduction 28 
1.5.2 Hypolipidemic agents from Fungi 31 
1.6 Animal model 35 
1.7 Objectives 36 
CHAPTER TWO: MATERIALS AND METHODS 37 
2.1 Materials 37 
2.1.1 Mushroom samples and control 37 
2.1.1.1 Sample introduction 37 
2.1.1.2 Sample collection 40 
2.1.1.3 Sample preparation 41 
2.1.1.4 Moisture content 45 
2.1.2 Animal diets for different experiments 45 
2.1.2.1 Basal diet 45 
2.1.2.2 Diet for preliminary screening 46 
2.1.2.3 Diet for dosage experiment 46 
2.1.2.4 Diet for active ingredient experiments 47 
2.1.2.5 Diet for long-term feeding experiment 47 
2.1.3 Animal model 49 
2.2 Methods 49 
2.2.1 Nutritional components of mushroom samples 49 
ix 
2.2.1.1 Crude protein content (Kjeldahl method) 49 
2.2.1.2 Total dietary fiber content 50 
2.2.1.3 Crude lipid content 52 
2.2.1.4 Ash content 53 
2.2.1.5 Moisture content 53 
2.2.2 Animal handling experiments 54 
2.2.2.1 Feeding experiment standards 54 
2.2.2.1.1 Feeding experiments of preliminary screening test 54 
2.2.2.1.2 Feeding experiments of dosage test 55 
2.2.2.1.3 Feeding experiments of solvent extracts from Agrocybe aegerita 
(Brig) Sing (AA) 56 
2.2.2.1.3.1 Fractionation of ethanol & water soluble components of AA.....56 
2.2.2.1.3.2 Feeding experiments of ethanol & water soluble components of 
AA 57 
2.2.2.1.4 Feeding experiment of long-term test 58 
2.2.2.2 Blood sample collection 58 
2.2.2.3 Serum preparation 58 
2.2.2.4 Liver sample preparation 58 
2.2.2.5 Fecal sample preparation 59 
2.2.3 Determination of serum lipid profiles 59 
2.2.3.1 Serum total cholesterol (TC) assay 59 
2.2.3.2 Serum triglyceride (TG) assay 60 
2.2.3.3 Serum high-density lipoprotein (HDL) cholesterol assay 61 
2.2.3.3.1 Separation of HDL fraction 61 
2.2.3.3.2 HDL cholesterol (HDL-c) determination 61 
2.2.4 Determination of liver lipid profiles 62 
XV 
2.2.4.1 Liver total cholesterol (TC) level determination 62 
2.2.4.2 Determination of liver total lipid (TL) level 64 
2.2.5 Quantitative determination of fecal neutral & acidic sterols 64 
2.2.5.1 Separation of fecal neutral & acidic sterols 64 
2.2.5.2 Derivatisation of fecal neutral sterols 65 
2.2.5.3 Derivatisation of fecal acidic sterols 65 
2.2.5.4 Gas chromatographic analysis of fecal neutral & acidic sterols 66 
2.2.6 Assays of liver key enzymes in cholesterol metabolism 67 
2.2.6.1 Preparation of hepatic microsome 67 
2.2.6.2 Assay of HMG-CoA reductase activity 68 
2.2.6.3 Assay of CYP7A activity 69 
2.3 Data statistics 71 
CHAPTER THREE: RESULTS AND DISCUSSION 72 
3.1 Preliminary screening of eleven mushrooms for their hypolipidemic effect in 
hyperlipidemic S.D. rats 72 
3.1.1 Body weight and food intake 73 
3.1.2 Effect of mushroom supplementation on serum lipid profiles 75 
3.1.2.1. Effect of mushroom supplementation on serum TC levels 75 
3.1.2.2. Effect of mushroom supplementation on serum TG levels 77 
3.1.2.3. Effect of mushroom supplementation on serum HDL levels 79 
3.1.2.4 Discussion of serum lipid profiles of S.D. rats fed M.S. diets in 
mushroom screening experiments 83 
3.1.3 Effect and discussion of mushroom supplementation on hepatic lipid 
profiles 84 
3.1.4 Effect and discussion of mushroom supplementation on fecal neutral sterol 
excretion 87 
xi 
3.1.5 Summary (mushroom screening experiments) 90 
3.2 Hypolipidemic effect of Agrocybe aegerita (Brig.) Sing (AA) in a dose response 
study in hyperlipidemic S.D. rats 91 
3.2.1 Nutritional composition of AA mushroom 91 
3.2.2 Body weight and food intake 91 
3.2.3 Effect of three different dosages of AA mushroom supplementation on blood 
lipid profiles of S.D. rats 93 
3.2.3.1 Effect of different dosages of AA mushroom supplementation diets on 
serum TC level 93 
3.2.3.2 Effect of different dosages of AA mushroom supplementation diets on 
serum TG level 93 
3.2.3.3 Effect of different dosages of AA mushroom supplementation diets on 
serum HDL level 95 
3.2.3.4 Discussion of different dosages of AA mushroom supplementation diets 
on serum lipid profiles 97 
3.2.4 Effect and discussion of three different dosages of AA mushroom 
supplementation on hepatic lipid profiles 98 
3.2.5 Effect and discussion of three different dosages of AA mushroom 
supplementation on fecal neutral & acidic sterol excretion 101 
3.2.6 Summary (dose response study) 105 
3.3 Hypolipidemic effect of ethanol extract (E.E.) & water extract (W.E.) from AA in 
hyperlipidemic S.D. rats 106 
3.3.1 Extraction yield 106 
3.3.2 Body weight & food intake 106 
3.3.3 Effect of AA extract supplementation on serum lipid profiles 107 
3.3.3.1 Effect of AA extract supplementation on serum TC level 107 
xii 
3.3.3.2 Effect of AA extract supplementation on serum TG level 108 
3.3.3.3 Effect of A A extract supplementation on serum HDL level 109 
3.3.4 Effect of AA extract supplementation on hepatic lipid profiles I l l 
3.3.5 Effect of AA extract supplementation on fecal neutral & acidic sterols 
excretion I l l 
3.3.6 Discussion (active fraction extract study) 113 
3.4 Long-term evaluation of the hypolipidemic effect of AA supplementation in 
normolipic S.D. rats 116 
3.4.1 Body weight & food intake 116 
3.4.2 Effect of long term AA supplementation on serum lipid profiles 117 
3.4.2.1 Effect of long term AA supplementation on serum TC level 117 
3.4.2.2 Effect of long term AA supplementation on serum TG level 118 
3.4.2.3 Effect of long term AA supplementation on serum HDL level 119 
3.4.3 Effect of long term AA supplementation on hepatic lipid profiles 119 
3.4.4 Effect of long term AA supplementation on fecal neutral & acidic sterols 
excretion.� 121 
3.4.5 Effect of long term AA supplementation on hepatic key enzymes of 
cholesterol metabolism — HMG-CoA reductase and CYP7A 123 
3.4.5.1 Quantitation of hepatic microsomal protein 123 
3.4.5.2 Effect of long term AA supplementation on HMG-CoA reductase activity 
in S.D. rats 124 
3.4.5.3 Effect of long term AA supplementation on CYP7A activity in S.D. 
rats 124 
3.4.7 Discussion (long-term study) 126 
CHAPTER FOUR: CONCLUSION AND FUTURE PERSPECTIVES 130 
References 136 
xiii 
List of Tables 
Pages 
Table 1-1 Composition and function of the major classes of lipoproteins 3 
Table 1-2 Hypolipidemic effects of some common edible and medicinal 
mushrooms 34 
Table 2-1 Diet ingredient composition table for in vivo experiments 48 
Table 3-1 The food intake and body weight of S.D. rats in the batch preliminary 
screening experiments 74 
Table 3-2 The food intake and body weight of S.D. rats in the batch preliminary 
screening experiments 74 
Table 3-3 The food intake and body weight of S.D. rats in the batch preliminary 
screening experiments 74 
Table 3-4 The fecal neutral sterol excretion of S.D. rats in some selected mushroom 
supplemented groups in screening experiments 87 
Table 3-5 The food intake and body weight gain of S.D. rats in dose-response study of 
AA diets 92 
Table 3-6 The fecal neutral sterol excretion in S.D. rats fed AA supplementation diet 
with three different dosages 103 
Table 3-7 The fecal acidic & total sterols excretion in S.D. rats fed AA 
supplementation diets with three different dosages 103 
Table 3-8 The food intake and body weight gain of S.D. rats fed ethanol extract and 
hot water extract from AA mushroom 107 
Table 3-9 The fecal neutral sterol excretion in S.D. rats fed AA extract 
supplementation diets 113 
xiv 
Table 3-10 The fecal acidic & total sterol excretion in S.D. rats fed AA 
supplementation diets 113 
Table 3-11 The food intake and body weight results of S.D. rats in the long term 
evaluation of AA supplementation diets 116 
Table 3-12 The serum HDL, HDL/TC ratio and Athero. Index of S.D. rats in long 
term evaluation of AA supplementation diets 119 
Table 3-13 Excretion of fecal neutral & acidic sterols in S.D. rats of long term 
evaluation of AA supplementation diets 122 
X V 
List of Figures 
Pages 
Figure 1-1 The structure of plasma lipoprotein 2 
Figure 1-2 Front view of heart showing cross sections of arteries 6 
Figure 1- 3 Cholesterol homeostasis 12 
Figure 1- 4 Mevalonate biosynthesis regulated by HMG-CoA reductase 13 
Figure 1-5 CYP7A catalyze the catabolism from cholesterol to 7a-
hydroxycholesterol 15 
Figure 1-6 Chemical structure of B-Glucan from oats 21 
Figure 1-7 Chemical structures of plant sterols and stanols 23 
Figure 1-8 Chemical structure of alliin and allicin from garlic 24 
Figure 1-9 Chemical structures of tocopherols and tocotrienols 25 
Figure 1-10 The mushroom life cycle 30 
Figure 1-11 Chemical structure of eritadenine 32 
Figure 1-12 Chemical structure of lovastatin. 33 
Figure 1-13 Anatomy of the hamster stomach 35 
Figure 2-1 Eleven edible and medicinal mushrooms for the investigation of their 
hypolipidemic effect 42 
Figure 3-1 Serum total cholesterol level of S.D. rats in the batch mushroom 
screening experiments 76 
Figure 3-2 Serum total cholesterol level of S.D. rats in the batch mushroom 
screening experiments 76 
Figure 3-3 Serum total cholesterol level of S.D. rats in the batch mushroom 
screening experiments 76 
Figure 3-4 Serum triglyceride level of S.D. rats in the batch mushroom screening 
xvi 
experiments 78 
Figure 3-5 Serum triglyceride level of S.D. rats in the batch mushroom screening 
experiments 78 
Figure 3-6 Serum HDL cholesterol level (3-6A), HDL/TC ratio (3-6B) and Athero. 
Index (3-6C) of S.D. rats in the batch screening experiments 80 
Figure 3-7 Serum HDL cholesterol level (3-7A), HDL/TC ratio (3-7B) and Athero. 
Index (3-7C) of S.D. rats in the batch screening experiments 81 
Figure 3-8 Serum HDL cholesterol level (3-8A), HDL/TC ratio (3-8B) and Athero. 
Index (3-8C) of S.D. rats in the batch screening experiments 82 
Figure 3-9 Hepatic total lipid level (mg/g liver) of S.D. rats in the mushroom 
screening experiments 85 
Figure 3-10 Hepatic total cholesterol level of S.D. rats (mg/g liver) in the mushroom 
screening experiments 85 
Figure 3-11 Gas-liquid chromatography of fecal neutral sterol standards 88 
Figure 3-12 Fasting serum TC level in S.D. rats fed AA supplementation diets with 
three different dosages 94 
Figure 3-13 Fasting serum TG levels in S.D. rats fed AA supplementation diets with 
three different dosages 94 
Figure 3-14 Fasting serum HDL levels (3-14A), HDL/TC ratio (3-14B), and Athero. 
Index (3-14C) in S.D. rats fed AA supplementation diets with three different 
dosages 96 
Figure 3-15 Hepatic total lipid level (mg/g liver) in S.D. rats fed AA supplementation 
diets with three different dosages 98 
Figure 3-16 Hepatic Total cholesterol level (mg/g liver) in rats fed AA 
supplementation diets with three different dosages 99 
Figure 3-17 Appearance of liver removed from S.D. rats fed the 5% AA diet as 
xvii 
compared to B.C. diet 100 
Figure 3-18 Gas-liquid chromatography of fecal acidic sterols standards 102 
Figure 3-19 Serum TC level in S.D. rats fed AA extract supplementation diets 108 
Figure 3-20 Serum TG level in S.D. rats fed AA extract supplementation diets 109 
Figure 3-21 Serum HDL cholesterol level (3-20A), HDL/TC ratio (3-20B) and Athero. 
Index (3-20C) in S.D. rats fed AA extract supplementation diets 110 
Figure 3-22 Hepatic total lipid level (mg/g liver) in S.D. rats fed AA extract 
supplementation diets 112 
Figure 3-23 Hepatic total cholesterol level (mg/g liver) in S.D. rats fed AA extract 
supplementation diets 112 
Figure 3-24 Serum TC level in S.D. rats fed AA supplementation diet during three 
months experiment 117 
Figure 3-25 Serum TG level in S.D. rats fed AA supplementation diet during three 
months experiment 118 
Figure 3-26 Hepatic total lipid level of S.D. rats in long term experiment of AA 
supplementated diet 120 
Figure 3-27 Hepatic total cholesterol level of S.D. rats in long term experiment of AA 
supplementated diet. 120 
Figure 3-28 Standard curve of Lowry protein assay (BSA) by absorbance at 
725nm 123 
Figure 3-29 Effect of hepatic HMG-CoA reductase activity in S.D. rats of long term 
experiment by AA supplementation diet 125 
Figure 3-30 Effect of hepatic CYP7A activity in S.D. rats of long term experiment by 
AA supplementation diet 125 
xviii 
List of Abbreviations 
Agrocybe aegerita (Brig.) Sing AA 
Agaricus blazei AB 
Agaricus campestris AC 
American Institute of Nutrition AIN 
Apolipoprotein Apo 
Blank control B.C. 
Coprinus comatus CC 
Cholesterol Ester Transfer Protein CETP 
Coronary Heart Disease CHD 
Cholesterol 7a-hydroxylase CYP7A 
Ethanol extract E.E. 
Food and Drug Administration FDA 
Gas-lipid chromatography GLC 
High-density lipoprotein HDL 
High-density lipoprotein cholesterol HDL-c 
Hericium Erinaceum HE 
3 -Hydroxy-3-methylglutaryl coenzyme A HMG-CoA 
Intermediate-density lipoprotein IDL 
lecithin-cholesterol acyltransferase LCAT 
Low-density lipoprotein LDL 
Low-density lipoprotein cholesterol LDL-c 
Lentinus giganteus LG 
Mushroom supplementation M.S. 
xix 
Poria cocos PC 
Pleurotus eryugii PE 
Pleurotus eryngii var. Nebrodensis PEVN 
Poly poms rhinoceros PR 
Pleurotus tuber-regium PTR 
Short chain fatty acid SCFA 
Sprague-Dawley rat S.D. rat 
Standard error SE 
Total cholesterol TC 
Total dietary fiber TDF 
Total lipid TL 
Thin-layer chromatography TLC 
Very low-density lipoprotein VLDL 
Water extract W.E. 
Weight/ volume W/V 
Weight/ weight W/W 
X X 
—— Chapter One： Introduction 
Chapter One: Introduction 
This thesis reports the investigation of the potential hypolipidemic effects of 
some Chinese edible and medicinal mushrooms. First of all, the lipid (especially 
cholesterol) metabolism will be introduced as the background information, beginning 
with the structure of different lipoproteins and their functions, then followed by the 
different risk factors of Coronary Heart Disease (CHD), which is a chronic disease in 
modem society with very high mortality. After that, cholesterol homeostasis will be 
discussed, with a focus on the two rate-limiting hepatic enzymes in cholesterol 
metabolism, as well as the by-products of fermentation in the colon一short chain fatty 
acids (SCFAs). The last part of the introduction will cover different hypolipidemic 
agents, such as some functional foods and pharmacological drugs, as well as a mini-
review on the potential hypolipidemic effect of edible and medicinal mushrooms. 
1.1 Different lipoproteins and their functions 
Lipoproteins are globular, high molecular weight particles that are complex 
aggregates of lipid and protein molecules (Figure 1-1). A lipoprotein consists of a 
hydrophobic core, which mainly contains triglycerides and cholesteryl esters, and a 
polar hydrophilic coat composed of phospholipids, unesterified cholesterol, and 
specific apolipoproteins. In this way, the hydrophobic core of lipoproteins is protected 
from the aqueous surrounding and transport large amounts of cholesterol and 
triglycerides by lipoproteins through the blood vessels in the extracellular 
compartments between the intestine, liver, adipose tissue and other peripheral organs 
(Mensink et al, 2002). 
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Figure 1-1: The structure of plasma lipoprotein. 
(Adapted from Leon et al., 2001) 
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There are four major classes of lipoproteins. They are (in order of decreasing 
percentage of lipid and increasing density) chylomicrons, very-low density lipoprotein 
(VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL). All 
lipoproteins carry triglycerides and cholesterol in different amount. The first and the 
second classes of lipoproteins transport more triglycerides, while the last two 
transport more cholesterol. 
The various classes of lipoprotein particles constituted by different 
apolipoproteins are responsible for important functions in secretion, cell recognition 
and activation of participating enzymes (Table 1-1). 
Table 1-1. 
Composition and function of the major classes of lipoproteins 
(Adapted from Vrana, 1999) 
Particle Function Origin Fate Apolipoproteins 
Chylomicron Transports dietary triglyc- Gut and HDL Liver and HDL Apo B-48 
eride and cholesterol Apo Cll, CIII 
from gut to other tissues Apo E 
VLDL Transports triglyceride from Liver and HDL Converted into LDL Apo B-100 
liver to other tissues Apo CI, Cll, Clll 
Apo E 
LDL Transports cholesterol from Formed from ‘ Taken up by target Apo B-100 
liver to other tissues VLDL by liver cells 
(bad cholesterol) 
HDL Transports cholesterol to From chylomicrons Liver Apo Al, All 
liver from other tissues and liver Apo B 
(good cholesterol) Apo CI, Cll, Clll 
Apo D 
Apo E 
Apo, apolipoprotein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. 
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1.1.1 Chylomicrons 
Chylomicrons are synthesized by the intestine but derive some apolipoproteins 
from HDL. The major function of chylomicrons is to transport triglyceride and 
cholesterol derived from the diet from the intestine to other tissues. The apo CII of 
chylomicrons can activate lipoprotein lipase in the capillary endothelium throughout 
the body to catalyze the hydrolysis of triglyceride to fatty acids, which are then taken 
up by cells of the tissues or organs. Chylomicron remnants return apolipoproteins to 
HDL, which are taken up and metabolized by the liver (Table 1-1). 
1.1.2 VLDL 
VLDL is synthesized by the liver and also receives apolipoproteins from HDL. 
The function of VLDL is to transport triglyceride from liver to extrahepatic tissues. 
Lipoprotein lipase catalyzes the hydrolysis and release of fatty acids from the core 
triglyceride. After transporting a portion of its triglyceride and after returning specific 
aplipoproteins to HDL, VLDL is converted into intermediate-density lipoprotein (IDL) 
and then into LDL by the liver (Table 1-1). 
1.1.3 LDL 
The main function of LDL is to transport cholesterol from the liver to 
extrahepatic tissues throughout the body. This process will enhance the serum TC and 
has been implicated as a potential risk factor in atherogenesis (1.2.2), so LDL is called 
"bad" cholesterol. Apolipoprotein B-lOO is the major protein on LDL membrane, and 
it can be recognized by specific plasma membrane receptors in most cells and most of 
them in liver (Table 1-1). LDL is taken up by the cell by receptor-mediated 
endocytosis and is delivered to the lysosomes. The latter degrade the apolipoproteins 
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and hydrolyze cholesterol ester to cholesterol. Cholesterol acts to decrease the 
synthesis of HMG-CoA synthase and HMG-CoA reductase (the two key enzymes in 
cholesterol biosynthesis), the LDL receptors, thereby decreases intracellular 
cholesterol levels as a dispersive control of cholesterol metabolism. 
1.1.4 HDL 
HDL is synthesized in the liver and donates and receives components from 
chylomicrons and VLDL, which are degraded by the liver (Table 1-1). The main 
function of HDL is to transport cholesterol from extrahepatic tissues throughout the 
body back to the liver, where the cholesterol can be catabolized and esterified. 
Therefore, HDL can reduce the serum total cholesterol especially the LDL cholesterol 
level and are inversely correlated with the incidence of Coronary Heart Disease 
(CHD). So HDL is called "good" cholesterol. Apolipoprotein A-I, is an activator of 
lecithin-cholesterol acyltransferase (LCAT) on HDL. On the surface of HDL, LCAT 
esterifies free cholesterol and lecithin to cholesterol ester and lysolecithin, transferring 
cholesterol ester to the interior of HDL and lysolecithin to albumin. It then motivates 
the continuous process of absorption of free cholesterol by the HDL. 
1.2 Risk factors of coronary heart disease (CHD) 
Like any other organ, the heart needs a constant supply of oxygen and nutrients 
that are carried to it by the blood in the coronary arteries. When the coronary arteries 
become narrowed or clogged and cannot supply enough blood to the heart, the result 
is coronary heart disease (CHD). 
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1.2.1 Background information of CHD 
CHD is caused by a thickening of the inside walls of the coronary arteries which 
called atherosclerosis (Figure 1-2). It narrows the space through which blood can flow, 
decreasing and sometimes completely cutting off the supply of oxygen and nutrients 
to the heart. The heart may respond with pain called angina, which has symptoms like 
chest and shoulder pain, however, the same inadequate blood supply may cause no 
symptoms, a condition called silent angina. In recent decades, CHD has become the 
number one killer of human being in western countries and its incidence in 
developing countries is increasing such as in China (NIH Publication, 1993). 
Front View of Heart Showing Cross Sections of Arteries 
Figure 1-2 Front view of heart showing cross sections of arteries (Adap ed from NIH Publication, 1993) 
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It was recognized over the past century that the role of high fat or high 
cholesterol diet in the development of both hyperlipidemia and atherosclerosis in 
animal models or humans (Ginsberg and Karmally, 2000). In the early part of the 
century, the rising incidence of CHD paralleled increased caloric intake, particularly 
intake of saturated fats. During World War II, the incidence of CHD dramatically fell 
in occupied countries. By contrast, after the war, Japanese persons who migrated to 
Hawaii who consumed increased quantities of saturated fats in diets, had increased in 
their serum cholesterol level and began to suffer more and more from CHD (National 
Research Council, 1989). During the past decades, a switch from a high-carbohydrate 
to a high-fat diet paralled the epidemic of CHD in many developing countries with 
their economy developing, while at the meantime, with the reduction in dietary 
consumption of fat had correlated with the reduction in CHD observed in the United 
States (Ginsberg and Karmally, 2000). 
The classic independent risk factors for CHD include hypertension, 
hypercholesterolemia, smoking, plasma total homocysteine and psychosocial factors 
(Boers 1997; Graham et al., 1997; Hallman 2000). 
1.2.2 Relationship between serum total cholesterol (TC), Low-density 
lipoprotein (LDL) cholesterol and CHD 
It has been demonstrated that hypercholesterolemia is an important independent 
risk factor for CHD. Numerous epidemiologic studies have been performed and 
implicated an elevated serum TC, especially LDL cholesterol level as an single, 
independent risk factor for the development of CHD (Heyden et aL, 1971; Hill and 
Wynder, 1976; Castelli et al., 1986). For instance, a recent large——scale cohort study 
had demonstrated a continuous, graded relationship of serum cholesterol level to long-
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term risk of CHD, and men with unfavorable serum cholesterol levels (200-239 
mg/dL and ^240 mg/dL) had strong gradients of relative mortality risk (Stamler et al., 
2000). Furthermore, with pharmacological intervention, many clinical studies have 
proved that lowering elevated serum TC levels, and particularly LDL-cholesterol 
levels, reduces the frequency of coronary morbidity and mortality (Matsuzaki et al., 
2002; Castano et al., 2003). Besides, it was demonstrated that high dietary cholesterol, 
especially dietary saturated fatty acids, has a positive correlation to high incidence of 
atherosclerosis due to elevated serum TC and LDL cholesterol levels (Parkard et al., 
1983; Denke and Grundy, 1992; Cater et al,, 1997). 
1.2.3 High-density lipoprotein (HDL) cholesterol and CHD 
Some epidemiologic studies have consistently demonstrated that plasma 
concentrations of HDL-cholesterol levels are inversely correlated with the incidence 
of CHD (Miller and Miller, 1975; Gordon and Rifkind, 1989). Two major hypotheses 
have been presented to explain such negative association between the plasma HDL-
cholesterol concentration and the CHD incidence: 
Firstly, a large body of data indicates a role for HDL in the reverse transport of 
cholesterol from tissues throughout the circulatory system back to the liver, where the 
cholesterol can be converted to bile acids, sex or adrenal steroid hormones 
(Franceschini et al, 1991; von Eckardstein et al., 2001). 
Secondly, HDL relates to its role as an antioxidant and antiaggregant in the 
vessel wall. It has been shown that apo A-I (the major apolipoprotein of HDL) can 
directly protect LDL against oxidative modification in vitro (Decossin et al., 1995). 
Another research showed the striking ability of human apo A-I to prevent progression 
of aortic atherosclerosis in mice with severe hypercholesterolemia. In such mouse 
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model of apo-E deficient, over expression of the gene for apo A-I resulted in 
significant antioxidant effects despite a very small increase in plasma HDL— 
cholesterol levels (Shah et al., 1998). 
1.2.4 Triglyceride and CHD 
Despite extensive analysis in numerous studies, controversy persists as to 
whether plasma triglycerides (TG) are an independent risk factor for CHD. In an early 
study in 1950, Albrink and Man showed that fasting TG levels were increased among 
CHD cases compared to control subjects (Albrink and Man, 1959). It has been 
demonstrated in an early cohort study that there was an increase in the incidence of 
ischemic heart disease (IHD) among men with elevated TG levels, compared with 
those with low TG levels (Brown el al., 1965). Even in the early studies, the scientists 
conjectured that the TG might not be an independent risk factor association with 
coronary mortality, since other plasma lipid levels were neglected. 
In the following decades, an extensive literature on examining the role of TG as 
a risk factor for CHD has been developed. Austin (1991) reviewed that most studies 
showed a relationship between TG and CHD. However, many other studies found that 
this association did not remain statistically significant after adjustment for combined 
risk factors, especially plasma HDL cholesterol and glucose levels (Criqui et al., 
1993). Further controversy stems from an absence of TG in vessel wall lesions and 
the lack of strong evidence that TG is an independent predictor of disease (Hall, 1995). 
After reviewing this and other evidence, the National Institutes of Health Consensus 
Development panel on TG, HDL, and CHD concluded that the data for triglycerides 
are mixed, although strong associations were found in some studies, the evidence for 
a causal relationship was still incomplete (Austin, 1991). 
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In recent years, two major academic camps with positive (Austin and Hokanson, 
1996) and negative (Kannel and Wilson, 1992; Forrester, 2001) views on the 
independent association between TG and CHD still existed. And other opinion 
combined the low HDL-cholesterol and high TG levels as one risk factor of CHD 
(Fruchart and Duriez, 2002). Thus, the role of triglyceride as an independent risk 
factor for CHD remains to be fully determined. 
1.3 Cholesterol homeostasis 
Cholesterol is very important for a multitude of critical cellular functions. For 
example, it is necessary for normal membrane structure and function; it is required for 
cell growth; it is a precursor for bile acids, steroid & sex hormones and vitamin D3； 
and in liver and intestine, it is important for normal lipoprotein synthesis and secretion. 
Thus, it is vital that the cells maintain an ample and continuous supply of this sterol. 
On the contrary, excess accumulation of this sterol will cause cell death. So the 
amount of cholesterol within a mammalian cell is tightly controlled. This critical 
balancing act implies the importance of the total body cholesterol homeostasis (Field, 
2001). 
Under physiological conditions, cholesterol homeostasis is maintained via 
dietary intake, intestinal absorption & secretion, lipoprotein transportation, regulated 
pathways of de novo synthesis, esterification and catabolism (Millatt et al., 2002) 
(Figure 1-3). 
Specifically, the following metabolisms are involved in the total body cholesterol 
homeostasis: Firstly, the cholesterol endogenous synthesis, from acetyl-CoA, is 
regulated primarily by the activity of 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase, which catalyzes the formation of mevalonate from HMG-
10 
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Co A (Brown and Goldstein, 1980); secondly, utilization of circulating lipoprotein 
cholesterol, by capturing the lipoprotein (especially the LDL) via a specific cell 
surface receptor, where lipoproteins are internalized and degraded, releasing 
cholesterol that can then be used by the cell (Brown and Goldstein, 1983); thirdly, 
esterification of the free cholesterol and CoA-derivatives of fatty acids to cholesteryl 
ester, is catalyzed by the acylcoenzyme A: cholesterol acyltransferase (ACAT) 
(Devery et al., 1987); fourthly, the catabolism of cholesterol to bile acids, the major 
degradation pathway for cholesterol that is regulated by the cholesterol 7a-
hydroxylase (CYP7A), which catalyzes the formation of 7a-hydroxycholesterol 
(Myant and Mitropoulos, 1977). 
Among the cholesterol homeostasis, liver and intestine are the two most critical 
organs. In liver, the hepatic HMG-CoA reductase provides the fastest rate and most 
total net amount of cholesterol synthesis. Furthermore, more than half of the LDL 
receptors are located in the liver (Brown and Goldstein, 1983) and the CYP7A is a 
hepatic enzyme. On the other side, intestine is the major site responsible for the 
absorption of dietary and biliary-derived cholesterol. Thus, the intestinal absorptive 
epithelial tissue is unique in the capacity to directly utilize dietary and biliary 
cholesterol from lumen (Field, 2001). In addition, cholesterol esterification is 
predominantly regulated by the intestinal ACAT (Haugen and Norum, 1976). 
Moreover, the intestine is also a site for the uptake and degradation of plasma 
lipoproteins like the clearance of circulating LDL in rodents (Dietschy et al., 1983); 
Finally, a new hypothesis of the short-chain fatty acids (SCFAs) formed after the 
fermentation of carbohydrates by colon bacteria which plays an important role in 
affecting plasma and hepatic cholesterol metabolism, has drawn more and more 
scientific interest and concern in the recent decades (Hara et al., 1999). 
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Figure 1-3 
Cholesterol homeostasis (Adapted from Nabel, 2003) 
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1.3.1 Roles of HMG-CoA reductase in cholesterol biosynthesis 
Endogenous cholesterol synthesis from Acetyl-CoA is a complex procedure with 
more than twenty steps. Among that, 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (mevalonate: NADP+ oxidoreductase [acylating CoA] EC 1.1.1.34) (HMG-
CoA reductase) is the major regulatory enzyme of this intracellular cholesterol 
biosynthesis in liver and intestine (Hulcher and Oleson, 1973; Stange et aL, 1981). It 
catalyzes the step of reducing HMG-CoA to mevalonate, by the electrons donate from 
NADPH and it is the rate-limited step in the whole cholesterol biosynthesis (Retey et 
al., 1970) (Figure 1-4). 
O O 
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HMG-CoA reductase activity can be regulated by exogenous cholesterol, its 
derivatives (oxysterol, cholestyramine) and key intermediates (mevalonate) in two 
ways: acute and long-term effect (Kandutsch, and Chen, 1973). In short-term 
regulation, an elevated cholesterol concentration in chylomicron remnants after diet, 
is a strong suppressor signal for HMG-CoA reductase, which lowers the enzyme 
activity by rapid inactivation of preformed enzyme up to 97% in turkey liver 
(Mitchell et al., 1985). Both in vitro and in vivo, the enzymatic activity of HMG-CoA 
reductase is modulated by reversible phosphorylation- dephosphorylation in a bicyclic 
cascade system (Beg et al., 1978, 1979; Keith et al., 1979). During this modulation, 
glucagon stimulates dephosphorylation of HMG-CoA reductase which then inhibits 
the enzyme activity while insulin plays the opposite role by stimulate the 
phosphorylation (Dugan et al., 1974; Beg et al., 1980). The long-term effect of HMG-
CoA reductase by cholesterol feeding is achieved by reduction in enzyme synthesis 
(Higgins et al., 1974). Due to the above regulations especially after the ingestion of 
dietary cholesterol, it is confirmed that a diurnal variation of HMG-CoA reductase 
activity exists, which causes the circadian rhythm of cholesterol biosynthesis both in 
liver and in intestine (Edwards et al., 1972; Shefer et al,, 1972). 
With the critical role played in the endogenous cholesterol synthesis, HMG-CoA 
reductase may be the best target to regulate the hypercholesterolemic disease. 
Actually, many HMG-CoA reductase inhibitors such as simvastatin, pravastatin, 
atorvastatin, lovastatin are used as hypolipidemic agents in medicine (These will be 
discussed in 1.4.2.). All of these drugs inhibit and reduce the intracellular cholesterol 
synthesis ability, so as to “consume” more plasma cholesterol especially the LDL 
cholesterol, which finally decreases the risk of CHD. 
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1.3.2 Roles of cholesterol 7a—hydroxylase (CYP7A) in cholesterol 
catabolism 
Cholesterol 7 a—hydroxylase (EC 1.14.13.17) (CYP7A) catalyzes the 
introduction of a 7a一hydroxyl group into the nucleus of cholesterol and forms two 
primary bile acids: cholic acid and chenic (chenodeoxycholic) acid in liver 
microsomes (Figure 1-5). It is the first and the rate-limiting enzyme that catalyzes this 




八 J - ^ 7a-Hydroxycholesterol 
Figure 1-5 
CYP7A catalyze the catabolism from cholesterol to 7a-hydroxycholesterol 
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Several mechanisms have been suggested concerning the regulation of this 
hepatic enzyme activity. The major one is a negative-feedback mechanism by the bile 
acids, especially the hydrophobic bile acids, returning to the liver via the portal vein 
(Myant and Mitropoulos, 1977). In the normal physiological status, most of the bile 
acids will be reabsorbed and returned to the liver from the intestine, which is known 
as an enterohepatic circulation of bile acids. This will inhibit the CYP7A activity to a 
lesser extent and just a low dose of bile acids are synthesized to balance the daily loss 
via the fecal excretion. However, when a biliary drainage of bile acids by bile fistula 
or cholestyramine treatment occurs, the rate of bile acid synthesis increases about 
tenfold (Thompson and Vars, 1953). Subsequent investigations found that after 
duodenal infusions of taurochenate or taurocholate to increase the bile acid 
concentration in the portal blood, the bile acid synthesis was restored to the normal 
rate in bile-fistula rats (Bergstrom and Danielsson, 1958; Shefer et al,, 1969). The 
above observations suggest that bile acid synthesis is inhibited when an optimal 
concentration of preformed bile acids exists in the enterohepatic circulation. 
Corresponding increase in CYP7A activity in similar experiments has subsequently 
been demonstrated by Boyd (1969) using radioisotopic methods and by Bjorkhem 
(1975) using direct measurement of the production rate of 7 a -hydroxycholesterol in 
liver microsomes. 
Besides, other regulation mechanisms on CYP7A include: short term effect of 
phosphorylation and dephosphorylation, diurnal rhythm, oxysterols (especially 7-
ketocholesterol and 7a-hydroxycholesterol) inhibition, thyroid hormone stimulation, 
and etc. (Scallen and Sanghvi, 1983; Chiang et al,, 1990; Lyons and Brown, 1999). In 
recent years, a full-length CYP7A cDNA is available and the explanation of the 
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regulation mechanism of this enzyme appears to be at the gene transcriptional level 
(Li et al., 1990; Chiang et al,, 1993). 
As the two major key enzymes contributing to the endogenous cholesterol 
biosynthesis and degradation, CYP7A and HMG-CoA reductase maintain the 
cholesterol homeostasis balance. In many instances, CYP7A and HMG-CoA 
reductase activities are regulated coordinately in the same direction. For example, bile 
acids feeding depress the activity of both of them, while glucose feeding after a fast 
stimulates them (Takeuchi et al., 1974). 
1.3.3 Effects of Short-Chain Fatty Acid (SCFA) 
In mammalian colon and cecum, fermentable carbohydrates such as soluble 
dietary fibers, are fermented by enterobacterium and the metabolized end products are 
Short Chain Fatty Acids (SCFAs) of three major types: acetate, propionate, and 
butyrate. Acetate and propionate can be rapidly absorbed from the colonic lumen into 
the portal blood, and the former is used as an energy source by most nonhepatic 
tissues while the latter is used by liver only. Butyrate is the preferred energy source 
for colonocytes (epithelial cells lining the colon) (Lupton and Turner, 2000). 
In recent decades, SCFAs were proposed to affect plasma and hepatic cholesterol 
metabolism leading to a hypocholesterolemic effect (Hara et al., 1999). Nishimura 
and his colleagues (1993) reported that the cholesterol lowering effect of sugar-beet 
fiber disappeared when the cecum was resected. But the mechanism is still a subject 
of debate and may be multifactorial. One early theory was that SCFAs stimulate the 
large intestine to secrete more enteroglucagon that can against the cholesterol 
synthesis (Goodlad et al,, 1989). Another different mechanism, which remains 
controversial, is about the effect of propionate. It has been shown by some 
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investigators that propionate might inhibit the HMG-CoA reductase activity, while 
others shown some conflicting results in lowering hepatic cholesterol (Wright et al., 
1990; Demigne et al., 1995). Furthermore, acetate has been suggested to be involved 
in serum cholesterol lowering effect but the detail mechanism is still unknown and 
under extensive investigation (Hara, 1998). 
1.3.4 Related hormones 
Insulin & Glucagon 
Insulin and glucagon are the two key regulatory hormones for cholesterol 
homeostasis. Insulin promotes fatty acid synthesis by stimulating the HMG-CoA 
reductase activity both in liver and in intestine (Lakshmanan et al., 1973; Goodman et 
al., 1981). Furthermore, it accelerates triglyceride transfer from liver to adipose 
tissues and storage in these tissues (Hillgartner et al., 1995; Jerkins et al., 1995), as 
well as the regulation of triglyceride-rich lipoprotein metabolism of diabetics (Hirano 
et al, 1991). On the contrary, plasma glucagon level has a down-regulatory effect of 
cholesterol synthesis by suppressing intestinal HMG-CoA reductase activity 
(Goodman et al., 1981). It also plays a key role in the decrease of hyperlipidemia in 
renal failure patients (Frank et al., 1978). 
Diet with high soluble fiber may account for the lower postprandial plasma 
insulin concentration and higher plasma glucagon level than the conventional diet, 
which will be expected to cause a hypolipidemic effect (Grizard et al., 2001). 
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Estrogen 
From many clinical trials, endogenous sex steroids are believed to protect 
premenopausal women again the development of CHD (Stampfer et al, 1991; Walsh 
et al., 1991; Hong et al., 1992). Among them, estrogens have been reported to have a 
number of potentially beneficial effects on lipoprotein metabolism: at physiological 
oral dose, hepatic CYP7A activities increased; while at pharmacological oral dose, the 
hepatic LDL receptors expression is stimulated, resulting in drastic reduction of 
plasma LDL cholesterol level. While at both low and high doses, apo A-I synthesis is 
increased in a progressive manner to elevate the plasma HDL cholesterol (Angelin et 
al., 1992; Parini et al, 2000). 
Furthermore, the phytoestrogen from soy may account for 60 to 70 percent of the 
hypocholesterolemic effects of soy protein in Rhesus monkey (Anthony et al., 1995). 
The attempts of hormones replacement therapy have varying effects which may 
be related to different species, sex, initial hormonal status (eg, for estrogen, 
postmenopausal versus fertile), differences in dose and efficiency between hormones 
preparations, as well as the mode of administration (oral versus percutaneous) 
(Moorjani et al., 1991). It still needs further clinical trials to develop a mature 
practical pharmacological protocol. 
1.4 Possible mechanisms of hypolipidemic agents 
It is acceptable that efforts to decrease plasma TC and reduce the risk for CHD 
should start with a health diet. In general, diet modification should focus on reducing 
the intake of dietary cholesterol and saturated fatty acids, as well as the excessive 
caloric intake before using pharmacological therapy. 
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1.4.1 Hypolipidemic functional foods 
In recent decades, although without a specific definition, any food that exerts as 
positive impact on health, in addition to its natural nutritional contribution, might be 
considered a "functional food". Within it, the hypolipidemic functional foods have 
drawn a great academic interest. And many studies have shown that there is a close 
relationship between hypolipidemic and reduced risk of CHD with the ingestion of the 
following nutrients including: dietary fiber, soy protein, plant sterols & stanols, garlic 
and tocotrienols (Kerckhoffs et al., 2002). 
Dietary fiber (P-Glucan) 
Dietary fibers include a variety of plant substances, mainly nonstarch 
polysaccharides and lignins, which are resistant to digestion by digestive enzymes. 
They can be classified into soluble and insoluble dietary fiber based on their water 
solubility. 
Although much attention has been given to the role of dietary fibers in lowering 
serum cholesterol effect, the mechanism is still a subject of debate and may depend on 
the type of fiber. The major hypothesis include: 1) fibers may increase the binding of 
bile acids in the intestinal lumen, which leads to a decreased enterohepatic circulation 
of bile acids and a subsequent increase in the hepatic cholesterol conversion; 2) the 
increase viscosity of the food mass because of soluble fibers leads to the formation of 
a thick unstirred water layer, adjacent to the mucosa in the small intestine. This layer 
may act as a physical barrier to reduce the absorption of bile acids; 3) fibers may 
delay gastric emptying and reduce the rate of glucose absorption, leading to a lower 
glycemic response and lower insulin concentrations which may result in a reduced 
hepatic cholesterol synthesis; 4) fermentation of soluble fibers in the colon results in 
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the production of short-chain fatty acid (SCFA), which may play a role in lowering 
serum and hepatic cholesterol concentration (as mentioned in 1.3.3) (Kerckhoffs et al,, 
2002) . 
A rich source of soluble dietary fiber is oats. p-Glucan from oats has been 
demonstrated to be an active hypolipidemic ingredient. It is a nonstrach 
polysaccharide composed of P-(l—4)-linked glucose units separated every two to 
three units by a single P-(l—3)-linked glucose (Figure 1-6) (Bell et al., 1999). The 
most plausible mechanism of its hypolipidemic effect is by its viscosity interfering 
with reabsorption of bile acids and hence producing a negative sterol balance (Lund et 
al, 1989). On the other hand, P-glucan from yeast {Saccharomyces cerevisiae) is 
composed with [P-( 1 ^ 6)-branched], [P-(l—3)-linked linear backbone]. Unlike oat (3-
glucan, yeast-derived P-glucan has a low viscosity and solubility in water and its 
hypolipidemic effect needs to be determined (Bell et oL, 1999). 
In 1997, the U.S. Food and Drug Administration (FDA) approved a health claim 
on food products that “ a diet high in soluble fiber from whole oats (oat bran, oatmeal 
and oat flour) and low in saturated fat and cholesterol may reduce the risk of heart 
disease." 
C H ^ H C H ^ H CH5OH C H ^ H C H - p H 
j OH I I I OH 
m OH OH OH OH 
Figure 1-6 
Chemical structure of B-Glucan from oats (Adapted from Bell et al., 1999) 
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Soy protein 
Soy protein is another focus with hypolipidemic function. Its possible 
mechanisms include an increase in LDL receptor activity, an increase in the synthesis 
and fecal excretion of bile acids, a suppression of cholesterol absorption (Potter, 
1995). Furthermore, it has been suggested that phytoestrogens found in soy may 
account for 60-70% of the hypolipidemic effects observed refer to 1.3.4 (Anderson et 
al., 1995; Anthony et al., 1995). 
In 1999, the U.S. FDA approved a health claim that “ 25g of soy protein a day, 
as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart 
disease." 
Plant sterols and stands 
Plant sterols, of which campesterol, P-sitosterol and stigmasterol (Figure 1-7) are 
the most abundant in nature, are structurally related to cholesterol, but with a different 
side-chain configuration. Saturation of these plant sterols with hydrogen leads to the 
formation of the plant stands, campestanol and sitostanol (Ling and Jones, 1995). 
Plant sterols and stands have a greater affinity for micelles than cholesterol 
because of their greater hydrophobicity. Therefore, they can easily displace intestinal 
cholesterol from the micelles, reducing intestinal cholesterol absorption (Plat and 
Mensink, 2001). This reduction in cholesterol absorption resulted in a compensatory 
increase in hepatic cholesterol synthesis and LDL-receptor expression, with the 
overall net effect of lowering the circulating LDL cholesterol concentration. 
In 2002, the U.S. FDA has concluded that "based on the totality of the publicly 
available scientific evidence, plant sterol and stanol esters may reduce the risk of 
CHD.,， 
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Figure 1-7 
Chemical structures of plant sterols and stands 
(Adapted from Ling and Jones, 1995) 
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Garlic 
A large number of intervention trials of garlic {Allium sativum) have been 
published. After crushing, cutting or chewing the garlic clove, the enzyme alliinase 
acts on alliin to produce allicin (Amagase et al, 2001). Allicin, which causes the 
characteristic garlic odor, is believed to be the active lipid-lowering compound in 
garlic (Figure 1-8) (Ali et al, 2000; Amagase et al., 2001). It may inhibit the 
synthesis of cholesterol and fatty acids in the liver as shown in animal studies. 
Furthermore, the garlic supplementation may inhibit atherosclerotic plaque formation 
by reducing thromboxane formation by platelets (Efendy et al., 1997). However the 
mechanism underlying the possible lipid-lowering action of garlic is not well 
understood and remains controversial. 
o 




Chemical structure of alliin and allicin from garlic 
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Tocotrienols 
Tocotrienols is one subgroup of the vitamin E family, which consists of a 
chromanol ring attached to a phytyl side chain (Figure 1-9). It is commonly presented 
in palm oil and rice bran oil. The tocotrienols differ from the tocopherols in that they 
have unsaturated phytyl side chains. Ri, R2 and R3 are rest-groups on the chromanol 
ring. Four subtypes of tocopherols and corresponding tocotrienols have been 
identified as: ^-(5, 7, 8-trimethyl), B-(5, 8-dimethyl), 7-(7, 8-dimethyl) and l-(8-
methyl) based on the number and position of methyl groups on the chromanol ring 






Chemical structures of tocopherols and tocotrienols 
(Adapted from Hunt and Groff, 1990) 
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Tocotrienols have been suggested to lower plasma cholesterol concentration, 
possibly because of an inhibition of the activity of HMG-CoA reductase, as 
demonstrated in animals (Qureshi et al., 1986). The mechanism of this inhibitory 
effect may involve a reduced HMG-CoA reductase protein synthesis rate and an 
increased degradation rate as found in human hepatoma HepG2 cell (Parker et al., 
1993). The different tocotrienol subtypes seem to possess various degrees of 
hypocholesterolemic effect in following sequence: 6-tocotrienol >y-tocotrienol >a-
tocotrienol > |3- tocotrienol (Pearce et al., 1992). However, results concerning the 
hypocholesterolemic effects of tocotrienols in humans are controversial and 
inconsistent. It still needs more extensive studies to elucidate the active ingredient and 
the detailed mechanism. 
1.4.2 Pharmacological drugs 
HMG-CoA reductase inhibitors (Statins) 
As mentioned in 1.3.1, HMG-CoA reductase is the rate-limiting enzyme of 
endogenous cholesterol synthesis and inhibitors of HMG-CoA reductase are the major 
lipid-lowering drugs currently used. Most of them are statins, which can decrease 
LDL by as much as 60%, and also decrease triglyceride and VLDL cholesterol and 
increase HDL cholesterol 5-10% (Batiste and Schaefer, 2002). The drugs may 
enhance LDL-cholesterol clearance, but also decrease its synthesis. However, all the 
statins have a 1-2% incidence of reversible liver enzyme elevation, and occasionally 
cause muscle aches, GI tract upset, skin rash and headache (Cuchel et al,, 1977). 
The common used statins include: Lovastatin (Mevinolin) (Mevacor), 
Pravastatin (Pravachol), Simvastatin (Zocor), Fluvastatin (Lescol), Atorvastatin 
(Lipitor), and Rosuvastatin (Crestor). 
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Fibric acid derivatives 
These agents are peroxisomal proliferator activating receptor alpha agonists and 
increase lipoprotein lipase and apo A-II gene expression, resulting in a decrease in 
TGs and a modest increase in HDL-cholesterol (Batiste and Schaefer, 2002). They 
include Gemfibrozil and Fenofibrate. 
Anion exchange resins 
The mechanism of the anion exchange resins depends on the affinity to bile acids 
in the lumen of the small intestine, enhancing the fecal disposal of bile acids. 
Consequently, conversion of hepatic cholesterol to bile acids is increased by 
stimulation of the CYP7A activity, together with the upregulation of LDL cholesterol 
receptors, which finally decrease plasma LDL cholesterol by about 20% (Davidson, et 
al., 1999). Side effects include bloating and constipation and elevation of plasma 
triglyceride level (The Lipid Research Clinics Coronary Primary Prevention Trial 
Results II，1984). 
They include: Cholestyramine, colestipol, and colesevelam. 
Cholesterol Ester Transfer Protein (CETP) inhibitor 
The mechanism of this drug is to prevent the transfer of cholesterol ester from 
HDL-cholesterol to other lipoproteins. A CETP inhibitor from Pfizer is currently 
being tested. It is well tolerated, and raises HDL cholesterol about 60%, as well as 
lowering LDL cholesterol by 10-20% (Ordovas et al, 2000). 
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Fish oil capsules 
Fish oil capsules are useful as TG-lowering agents in patients who do not have 
an adequate response to gemfibrozil or fenofibrate. Among the lipids derived from 
marine vertebrates, the n-3 polyunsaturated fatty acids (PUFA) play a key protective 
effect on fatal cardiovascular events (GISSI-Prevenzione Investigators, 1999). Side 
effects are minimal which include slightly prolonged bleeding time, and a fishy odor 
with belching (Park et al., 2000). 
Combination therapy 
Beside the separated use, recently pharmacological studies show that a 
combination use of the above agents can greatly improve the hypolipidemic effect. 
For example, a combination of statin and a resin is quite effective in lowering LDL 
cholesterol. Gemfibrozil or fenofibrate combined with fish oil capsules can 
dramatically lower triglycerides in severe hypertriglyceridemia (Batiste and Schaefer, 
2002) . 
1.5 Edible and medicinal mushrooms 
1.5.1 General introduction 
Mushroom is a fleshy, spore-bearing organ of fungi. As the vegetative state, 
mycelium represents the longest phase in the mushroom life cycle. In response to 
environmental stimuli (such as decline in temperature, reduction in carbon dioxide, 
water and humidity, and so on), the mycelium is triggered into primordia, then 
develops into fruitbody, the reproductive phase of mushroom life cycle. In this phase, 
mushroom enlarges and differentiation of familiar features occurs. The cap, stem, veil, 
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and gills emerge. After the fruitbody is matured, it will liberate the spores to begin 
another life cycle (Figure 1-10). Furthermore, under inclement weather conditions like 
drought, flooding, fire or other natural catastrophes, many mushrooms can convert to 
a resting phasesclerot ia , Sclerotia resemble a hardened tuber, wood-like in texture. 
When the natural conditions turn better, a mushroom fruitbody can directly emerge 
from the sclerotia (Stamets, 1993). 
Since ancient times, mushrooms have been treated as a special kind of food due 
to its nutritional and therapeutic values. The Romans regarded mushrooms as the 
"Food of Gods," which was only served on festival occasions. The Chinese treasured 
them as "elixir of life" and some of them were recorded in the famous ancient treatise 
"Pen Ts'ao Kang Ma" as one type of valuable Chinese medicine (Chang and Miles, 
1989). 
In recent decades, mushrooms have received a remarkable amount of interest 
with the realization that they are a good source of delicious, health food that is rich in 
protein with balanced amino acid profiles, dietary fiber, but low in total calories and 
saturated fat (Aletor, 1995; Manzi et al., 2001). The amount of mushroom consumed 
has risen greatly, involving a large number of edible species. The production of 
cultivated edible mushrooms all over the world was estimated to more than 6 million 
tons in 1997 (Chang, 1999). Within them, six most popular species are: Agaricus, 
Lentinus, Pleurotus, Auricularia, Flammulina and Volvariella with a contribution up 
to 86.9% in total production. Furthermore, China has become the top one producer 
and consumer of cultivated mushrooms with around 4 million tons annual production, 
which accounted for 63.6% of the total world output in 1997. Within all the 
mushrooms, Lentinus edodes is the most popular species in China. 
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Figure 1- 10 
The mushroom life cycle (Adapted from Goodridge and Sul, 2000) 
On the other side, some edible mushrooms have become a new focus of 
academic interest in "functional food" because of their potential pharmaceutical 
values. Furthermore, many works have been done to extract the active ingredients 
from mushrooms in order to develop new drugs that are useful for their biological 
activities such as antioxidant, hypolipidemic, antiviral, antitumor effect (Liu et al” 
1999). 
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Focusing on the hypolipidemic property of mushrooms, a lot of studies have 
suggested that dietary fiber plays an important role in this field, such as fibers from 
Auricularia auricula (tree-ear) and Tremella fuciformis (white jelly-leaf) could 
significantly decrease the serum TC and LDL cholesterol level (Cheung, 1996b); 
fibers from Grifola Frondosa (maitake mushroom) could greatly increase the fecal 
sterol excretion to reduce the total body “sterol pools" (Kubo and Nanba, 1997); 
fibers from Flammulina velutipes (enokitake mushroom) and Agaricus bisporus 
(button mushroom) could dramatically enhance the hepatic LDL receptor mRNA to 
the diminution of the serum TC (Fukushima et al., 2000 and 2001). Furthermore, the 
most popular eastern and western edible mushroomsLentinus edodes and Pleurotus 
ostreatus respectively~which have attracted the most attention, have been believed to 
have the hypolipidemic effect as well as the active ingredient elucidation (details refer 
to 1.5.3). 
Nevertheless, the definitive hypolipidemic mechanisms of mushrooms still 
remain largely unknown, and a lot of intensive investigations need to be done to 
explore the newly-found and cultivated mushrooms as well as their active ingredients 
with potential therapeutic values. 
1.5.2 Hypolipidemic agents from Fungi 
Lentinus edodes (Shiitake mushroom) 
It has long been recognized that eritadenine (also known as lentinacin) [2(R), 
3(R)-dihydroxy-4-(9-adenyl)-butyric acid] (Figure 1-11), a compound extracted from 
Lentinus edodes is able to lower serum cholesterol level (Chibata et al, 1969). 
Eritadenine reduces serum cholesterol level in mice not by inhibition of cholesterol 
biosynthesis but by the acceleration of the excretion of ingested cholesterol and its 
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metabolic decomposition (Susuki and Oshima, 1974). Various studies have shown 
that Lentinus mushrooms can lower both blood pressure and free cholesterol in 
plasma, as well as accelerate the accumulation of lipids in the liver, by removing them 
from circulation (Kabir and Kumura, 1989). It has been suggested that high dosages 
of eritadenime may impair the secretion of very low-density lipoprotein cholesterol. 
Furthermore, similar to soybean protein, eritadenine lowers cholesterol by decreasing 
the ratio of phosphatidylcholine (PC) to phosphatidylethanolamine (PE) in liver 
microsomes and altered the molecular species composition of PC (Sugiyama and 
Yamakawa, 1996). Several other studies with Lentinus extracts in Japan have shown 
significant decrease in serum cholesterol in young women and people older than 60 
years of age (Hobbs, 1995). 
Figure 1-11 
Chemical structure of eritadenine f j 
(Adapted from Huang et. al., 2002). / / T 7 
. o C I N " ^ 
《 
HO OH 
Pleurotus ostreatus (oyster mushroom) 
Several Pleurotus edible mushroom species can produce mevinolin (also known 
as lovastatin) (Figure 1-12)—a powerful inhibitor of HMG-CoA reductase while P. 
ostreatus has been shown to produce the highest yield of it in the fruiting body, 
especially in the lamellae or gills (Cimerman and Cimerman, 1995). 
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It was found that the addition of 1% to 5% of oyster mushroom to the 
hyperlipidemic diet efficiently prevented accumulation of cholesterol (especially LDL 
cholesterol) and triglycerides in both the blood and liver of rats with hyperlipidemia 
(Bobek et al., 1998), as well as reduced cholesterol biosynthesis by suppressing the 
activity of hepatic HMG-CoA reductase (Bobek et al., 1995a) and accelerated 
cholesterol catabolism by up-regulating hepatic cholesterol 7a-hydroxylase (Bobek et 
al., 1994c). 
It has been suggested that fruiting bodies of oyster mushroom could be 
recommended for consumption as a natural cholesterol—lowering agent in human 
diet (Cimerman, 1999). 
Figure 1-12 O �� 
Chemical structure of H g C ^ ^ V ^ ^ ^ ^ O t ^ 
lovastatin CHg 
(Adapter from Loren, 2002) 
Other fungi 
Some common edible and medicinal mushrooms with hypolipidemic effects are 
summarized in Table 1-2. It can be seen that more investigations are required to study 
the many hypolipidemic mushroom species and their active ingredients, especially the 
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1.6 Animal model 
Sprague-Dawley rat (Rattus norvegicus) is commonly used as an animal model 
for studies of hypolipidemic and cholesterol metabolism (Cohen and Raicht, 1981; 
Emmons et al” 1988; Shin et al； 1999). Due to its high level of serum HDL, S.D. rat 
is resistant to the development of atherosclerosis even by feeding of a high cholesterol 
diet (Fantappie et aL, 1989). Thus, this animal model is particularly useful for 
preliminary screening of hypocholesterolemic agents. Hamster is another common 
animal for the study of lipodemic effect. Although the LDL profile of hamster is 
similar to human (Nistor et al., 1987), it has a big nonglandular forestomach (Figure 
1-13) that is different from the structure of human stomach. The forestomach in 
hamster is the site for fermentation of diet to produce different metabolic products in 
the gastrointestinal tract, which is not found in human (Field and Sibold, 1999). 
c 
Figure 1-13 
Anatomy of the hamster stomach 
The structures are: (A) esophagus; (B) nonglandular forestomach; 
(C) glandular stomach; (D) pyloric region of the stomach. 
(Adapted from Field and Sibold, 1999) 
35 
— Chanter One; Introduction 
1.7 Objectives 
The objectives of this research are to investigate the lipid- and cholesterol-
lowering effects of some lesser-known oriental edible and medicinal mushrooms that 
have potential commercial values in in vivo experiments. Firstly, a preliminary 
screening of eleven selected mushrooms with oat as a positive control was conducted 
in hypercholesterolemic S.D. rats. Secondly, a dose-response relationship on a chosen 
mushroom that had the most potent hypocholesterolemic effect was investigated. 
Thirdly, an extraction of the active hypolipidemic fractions of the chosen mushroom 
was carried out, followed by a 12 weeks feeding of normolipidemic S.D. rats with the 
mushroom supplementation for the determination of the hypolipidemic mechanisms in 
terms of cholesterol regulatory enzymes. 
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Chapter Two: Materials and Methods 
2.1 Materials 
2.1.1 Mushroom samples and control 
2.1.1.1 Sample introduction 
Eleven edible and medicinal oriental mushrooms were chosen for investigation 
of their hypolipidemic effect (Figure 2-1A to L). Most of them are newly developed 
cultivated species, with limited scientific research results on their lipid lowering effect. 
A brief introduction on some of these mushroom samples is as follows: 
Agrocybe aegerita (Brig.) Sing (AA) (Figure 2-1 A) 
Family of Bolbitiaceae. Morphological characteristics: Pileus is semi-sphere 
shape when young, then gradually spreads to flat, slightly eminences in the middle, 
3 �1 0 cm in diameter. The pileus surface is deep brown to dark brown when immature, 
then gradually turns to light brown and clay chryso-brown. The color in the pileus is 
lighter, sticky with moisture, smooth or with wrinkles in the middle. Flesh is muddy 
white, a little thick in the middle, and the edge is thinner. Lamella grows straightly or 
nearly curvedly, dense, aniso-length, white when young, then turns to dark 
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chryso-brown or brown. Stipe appears round, 3 � 9 cm in length, 0 .3�1.2 cm in width, 
dark white in anterior portion, gradually turns to light brown in posterior area. It has 
cilial shaped small ramentums, with a firm texture and rich of bends or distortions. 
Annulus grows from the top of stipe, white, membrane structure, with micro-stripes 
on the surface. It often appears brown because of the spore adhesion. Spores are 
oval-shape or ovi-round shape, light chryso-brown. Ecological characteristic: During 
the period of spring to autumn, it singly or multiply grows from the dry and rotten 
trunk and stump of teas or willows. Fruiting bodies are for Pharmacological usage and 
should be sun-dried before storage. The fermentation broth of A A contains saponin, 
triterpene saponin, amindos and polysaccharide. Distribution areas: In Jilin, Liaoning, 
Zhejiang, Fujian, Taiwan, Guizhou, Yunnan, and Sichuan provinces of China (Chen 
and Chen, 2000). 
Pleurotus eryngii (PE) (Figure 2-11) 
Family of Polyporaceae. Morphologic characteristics: Fruiting bodies are single, 
nest or multiple growth. Pileus is 2-11 cm in broad with hemisphere shape when 
young and becomes shallow with depression round to sector when matures. Surface is 
with polishing color like silk, smooth, dry, and like micro-fiber in shape. It is light 
ink-gray when immatures and light yellow in color when matures. Its center has the 
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black-brown micro-stripe with a radiation shape, and involtes in the edge and has 
spears wave shape at the end. Flesh is white with an almond smell. Lamella grows 
along the edge, dense, slightly broad, aniso-length, and ivory in color. Stipe leans to 
side growth with scarcely middle growth, 2-8 cm in length, 0.5-3 cm in broad, 
smooth in the surface, near white or slight yellow in color, full and flesh, fiber shaped. 
Spores are oval-shape or spin-hammer shape, achromatic color. Ecological 
characteristics: During the period of spring and early summer, it is bom from the 
caudex or root of the umbrella-shape flower bureau plants, for instant, pricking celery. 
Distribution areas: It can be cultivated. No mild distrubution in China, but it is 
cultivated in places such as Fujing and Taiwan provinces, with its original from 
Europe (Chen and Chen, 2000). 
Pleurotus eryngii var, Nebrodensis (PEVN) (Figure 2-1 J) 
Family of Polyoraceare. A newly cultivated hybridisation of P. eryngi and P. 
nebrodensis. Morphological characteristic: Fruiting bodies are single or multiple 
growth. Pileus evaginates at the beginning, then spreads flat, and inferiors fovea to 
shallow tilt funnel shape in the middle, 3-13 cm in length, white in color and edge 
involutes. Mushroom flesh is thick and its color is white. Lamella grows near the edge, 
dense, aniso-length, light chryso-white. Stipe grows centricly or eccentricly, 6-14 cm 
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in length, same caliber or thinner in the lower part, end white in color. Spores are 
rectanglar-oval or oval in shape, achromatic color. Ecological characteristics: During 
the period of late spring and early summer, it is bom fro mthe caudex or pedicle of the 
umbrella shape flower bureau plants, such as Chinese asafetida, Xinjiang asafetida, 
pricking celery, etc. Distribution areas: Northwestern part of Sichuan and Xinjiang 
provinces of China (Chen and Chen, 2000). 
2.1.1.2 Sample collection 
The mushroom samples were collected from two major sources: 
Firstly, some of them were from the Sanming Mycological Institute of the Fujian 
Province in China which included: 
1) Fruiting bodies of Pleurotus eryngii van Nebrodensis (PEVN) , Pleurotus eryugii 
(PE), Coprinus comatus (CC), Lentinus giganteus (LG); 
2) Sclerotia of Pleurotus tuber-regium (PTR)\ 
Secondly, the rest of them were purchased from local market which included: 
1) Fruiting bodies of Agrocybe aegerita (Brig.) Sing (AA), Agaricus blazei (AB), 
Hericium Erinaceum (HE), Agaricus campestris (AC); 
2) Sclerotia of Polyporus rhinoceros (PR), Poria cocos (PC); 
The identification of AA was done by Sanming Mycological Institute. 
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Whole Oats (General Mills, USA) were purchased from local market and served 
as the positive control with hypolipidemic effect. 
2.1.1.3 Sample preparation 
The fruiting bodies ofPEVN, PE, CC, LG, AA, AB, HE, and AC were cleaned 
to remove any debris and dust and then oven-dried at 60�C overnight. The moisture is 
less than 10% of the whole weight of dried mushroom. The dried sclerotia of PTR, PC 
and PR were brushed to remove the soil, mold and dust that adhered to their surfaces. 
All dried mushrooms were then ground by a hammer mill (IKA MF 10, IKA WERKE, 
Germany) to pass through a 0.5mm sieve and then stored in airtight plastic bags in a 
desiccator at room temperature for further analysis. 
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Figure 2-1: 
Eleven edible and medicinal mushrooms for the investigation of their 
hypolipidemic effect 
Figure 2-1 A: A A (茶薪薛） F igure 2 - l B : A B (巴西蘑） 
Figure 2-lC: AC (蘑薛） Figure 2-lF: CC (雞腿薛） 
I . • - • Ni. • I 
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Figure 2 - l E : H E (猴頭薛） F igure 2 - l D : L G (大斗薛） 
； --
Figure 2-lG: OATS (燕麥） 
(positive control) Figure 2-lH: PC (伏爷） 
43 
Chapter Two: Materials and Methods 
Figure 2-11: PE (剌斧側耳） Figure 2-1 J: PEVN (白阿魏蘑） 
I —二" ^ % . I ^ ^ H f t - i ^ ^ 
: • 义 、 E ^ l ‘ r l 
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Figure 2-lK: PR (虎乳靈芝） Figure 2-lL: PTR (虎奶薛） 
BHIHilHIiiliMiilfiMftiiifet^ ^ V 他 ^ 
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2.1.1.4 Moisture content 
The moisture content of the eleven mushroom powders was determined 
duplicated by an infrared moisture analyzer (Mettler LJ16, Greifensee, Switzerland). 
Infrared radiation of wavelength 2 |im to 3.5 |im with a temperature of 120�C were 
set in the analyzer. Two to three grams of each sample were weighed into a dry 
aluminum pan and then placed in the analyzer. The heating process was started and 
result (in term of % dry weight) was recorded and printed automatically every 30 
seconds. Measurement was taken whenever two identical results appeared 
consecutively. 
2.1.2 Animal diets for different experiments 
2.1.2.1 Basal diet 
A semi-synthetic diet for animal model based on the AIN 93M formula (Reeves 
et al. 1993) was used as the basal diet. The ingredients were (g/kg): sucrose (Taikoo, 
Taikoo Sugar Ltd.), 100; casein (Sigma C7078), 140; cornstarch (Kingsford's, 
CPC/AJI (HK) Ltd.), 466; dextrin cornstarch (Sigma D-2256), 155; soybean oil (no 
additives) (ICN Biomedical, INC. 104687), 40; cellulose (Harlan TEKLAD 160390), 
50； mineral mix (Harlan TEKLAD 692604), 35.0; vitamin mix (AIN-93-VX) (Harlan 
TEKLAD RX790543), 10; L-cystine (Sigma C-8755), 1.8; chloine bitartrate (Sigma 
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CI629), 2.5; tert-butylhydroquinone (Aldrich Chem.Co 11294-1), 0.008. 
2.1.2.2 Diet for preliminary screening 
The above basal diet which was based on the AIN 93M formula were modified as 
follows: (Table 2-1) 
1) Both in the blank control (B.C.) group and the eleven mushroom supplemented 
(M.S) groups, pure cholesterol powder (Sigma, C8503) at 2% by weight 
(Cheung, 1996a) were added to the diets to induce alimentary 
hypercholesterolemia, replacing the same amount of cornstarch. 
2) In the M.S.group, dry mushroom powder at 5% by weight (Bobek et al., 1995a, 
1995b, 1996) was added to replace the same amount of cornstarch. 
2.1.2.3 Diet for dosage experiment (Table 2-1) 
1) Both in the B.C. group and the M.S. groups, pure cholesterol powder (Sigma, 
C8503) at 2% by weight was added to the diet to induce alimentary 
hypercholesterolemia with the same amount of cornstarch being replaced. 
2) In three M.S. groups, dry mushroom powder was added at three different levels of 
50/0, 10% and 20%, respectively, with the adjustment of cellulose, casein and 
cornstarch content to form an isocaloric diet. 
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2.1.2.4 Diet for active ingredient experiments (Table 2-1) 
Both in the B.C. group and the M.S. groups, pure cholesterol powder (Sigma, 
C8503) at 2% by weight was added to the diet to induce alimentary 
hypercholesterolemia with the same amount of cornstarch being replaced. 
2.1.2.5 Diet for long-term feeding experiment (Table 2-1) 
1) In B.C. group, the diet was based on basal diet formula without any modification; 
2) In M.S. group, dry mushroom powder at 5% by weight was added with the 
adjustment of according cellulose, casein and cornstarch content to form an 
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2.1.3 Animal model 
Male weaning Sprague-Dawley rats {Rattus norvegicus) from the Laboratory 
Animal Services Center (The Chinese University of Hong Kong, Shatin, Hong Kong) 
of initial body weight of about 150g (4 to 5 wk) were used in all these experiments. 
2.2 Methods 
2.2.1 Nutritional components of mushroom samples 
2.2.1.1 Crude protein content (Kjeldahl method) 
The protein content of the mushrooms was determined by the Kjeldahl method 
(978.02) (AOAC, 1996). Each sample (around 0.5 g) with one piece of Kjetabs 
(potassium sulfate-copper sulfate) was placed into a Kjeldahl flask (750ml). At mean 
time, 10 ml 18M sulfuric acid was added to the flask with gentle shaking. The mixture 
was heated at 420�C in a Kjeldahl digestion apparatus (2006 Digester, Tecator, 
Sweden) until the solution became clear and the heating was continued for another 30 
min to ensure its complete oxidation. Each flask was covered with a funnel to reduce 
the evaporation of sulfuric acid during heating. When the oxidation was completed, 
the flask was cooled to room temperature. All the heating and cooling procedures 
were carried out in a fume cupboard. Then distilled water (75 ml) was added to each 
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flask carefully and the flask was placed inside the Kjeldahl distillation set (Kjeltec 
system, 1002 distilling system, Tecator, Sweden). Forty percent of sodium hydroxide 
(50 ml) was added into the flask to make the mixture alkaline. Steam was bubbled 
into the alkaline mixture in order to release the ammonia from the solution. Then the 
ammonia was carried into a conical flask containing 2% boric acid solution (50 ml) 
with its pH value previously adjusted to the screened methyl red end point. Finally, 
after about 150 ml of the distillate was collected in the conical flask, the mixture in 
the conical flask was titrated with O.IN hydrochloric acid and the percentage of 
nitrogen was calculated as following: 
% Nitrogen = [ Vol. ofHCl (ml) X normality ofHCl X 1.4]/ sample weight (g) 
% protein = % Nitrogen X 6.25 
2.2.1.2 Total dietary fiber content 
The content of total dietary fiber (TDF) in mushroom dry powder was 
determined according to the AO AC enzymatic gravimetric method (AO AC, 1995). In 
brief, duplicated 1.000±0.005g samples were weighed (Mi and M2), accurately to 
O.lmg, into 600ml tall-form beakers. Forty milliliters of MES-TRIS buffer solution at 
pH 8.2 were added to each beaker and stirred with a stirrer until the sample was 
completely dispersed to prevent lump formation. Then 50jil heat-stable a-amylase 
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(EC 3.2.1.1 from Bacillus licheniformis, catalog no. A3306, Sigma-Aldrich Chemical 
Co., St. Louis, MO) was added to the mixture and stirred at low speed. The beakers 
were covered with aluminum foil, and incubated in a 95-100�C water bath for 15 min 
with continuous agitation and timing was started once bath temperature reached 95�C. 
All beakers were removed from the bath and cooled to 60�C. Protease (100 |Lil)(from 
subtilisin Carlsberg, catalog no. P3910, Sigma-Aldrich) was added to each beaker 
covered with aluminum foil and incubated for 30 min with timing started once bath 
temperature reached 60�C. The aluminum foil was removed and 5ml 0.56IN H Q 
were dispensed into beakers while stirring. The pH was adjusted to 4.0-4.7 at 60�C, by 
adding IN NaOH solution or IN HCl. Finally amyloglucosidase (300|il) (EC 3.2.1.3 
from Aspergillus niger, catalog no. A9913, Sigma-Aldrich) was added while stirring 
and the beaker was covered with Aluminum foil, incubated for 30 min at 60±rC 
with constant agitation. And timing was started once the bath temperature reached 60 
�C. Then the enzyme treated mixture containing the buffer solution and non-digestible 
materials was precipitated with 4 volumes of 95% ethanol overnight at room 
temperature (20�C). After that, the ethanol-insoluble residue was filtered with a 
Fiber-Tec System (1023 Filtration module, Tecator, Sweden) and was further washed 
by 78%, 95% ethanol and acetone sequentially for three times. Finally, the recovered 
residue was oven-dried (105�C over night) to constant weight (Ri and R2) and 
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weighed to give the gravimetric yield of the TDF in mushroom samples. The weight 
of TDF was corrected for ash (determined separately by dry ashing procedure in 
2.2.1.4) and residual protein content (determined separately by Kjeldehl method in 
2.2.1.1) and a reagent blank control. 
TDF determination (g/lOOg): 
TDF = {[(Ri+ R 2 ) / 2 ] - P - A - B } / [(Mi+ M2)/2] X 100 
Where P and A equal to weights (mg) of residue protein and ash content, respectively; 
B equal to blank control weight (mg). 
Ml, M2 are the duplicated sample weight while Rl and R2 are the duplicated residue 
weight. 
2.2.1.3 Crude lipid content 
The crude lipid content of the mushroom samples was determined by the Official 
Methods of Analysis (963.13) (AOAC 1995) with some modifications. About five 
grams of mushroom dry powder was taken into a fat free thimble covering by some 
defatted cotton wool. Then the thimble was placed in a Soxhlet extractor (Soxtec 
System HT6, Tecator, Sweden) with a preheated oil bath (120�C), as well as a 
pre-weighed aluminum cup, which contained 50 ml petroleum ether( boiling point: 
60-80�C) as the extract solvent. During the lipid extraction, the thimble was immersed 
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in boiling petroleum ether at 120�C for one hour. After that, the thimble was pull to 
above the extract solvent and rinsed by the condensed solvent for another 60 minutes 
in order to extract the lipid as much as possible. After direct desolventizaiton in the 
apparatus, the dried aluminium cup containing the residual lipid was further oven 
dried (80�C) to a constant weight. Then after cooling in a desiccator, the amount of 
the residual oil (crude lipid) in the cup was determined gravimetrically. 
2.2.1.4 Ash content 
According to the Official Methods of Analysis (4.1.10) (AOAC, 1995), around 
one gram mushroom dry powder was weighed in a pre-weighed crucible and 
combusted overnight in a muffle furnace at 525�C. After cooled in a desiccator, the 
ash residue was calculated by weigh difference and expressed as percentage of 
mushroom sample dry weight. 
2.2.1.5 Moisture content 
Same as 2.1.1.3. 
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2.2.2 Animal feeding experiments 
2.2.2.1 Feeding experiment standards 
Male weaning Sprague-Dawley rats {Rattus norvegicus) from the Laboratory 
Animal Service Center of The Chinese University of Hong Kong of initial body 
weight 150g were randomly assigned to each group of eight. There were no 
significant differences in body weight and serum TC concentrations at the beginning 
of the experiment. Each animal was housed individually in stainless steel cages in an 
animal room at a 12-h light:dark (0600�1800) cycle. Temperature and humidity were 
controlled at IVC ±1�C and 70% ±50/0, respectively. The experimental protocols 
were reviewed and approved by the Committee of Animal Ethics of the Chinese 
University of Hong Kong. 
2.2.2.1.1 Feeding experiments of preliminary screening test 
The rats were randomly assigned into two groups, the B.C. group and the M.S 
group with eight animals each. All rats were fed the diets as shown in Table 2-1 in 
2.1.2.2 ad libitum for four weeks. Fresh diets were given to the animal daily and the 
food intake was measured daily, while the body weight was recorded once a week. 
In practice, all of the eleven mushrooms groups were divided into 3 batches with 
a B.C. group each, in which the second batch a positive control (whole oat) group was 
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added as comparison. The grouping of mushroom diets and controls was as following: 
ist batch: B.C. group; PE group; PEVN group; A A group and PR group; 
2nd batch: B.C. group; AB group; PC group; HE group; OAT group and AC 
group; 
3rd batch: B.C. group; PTR group; CC group and LG group. 
2.2.2.1.2 Feeding experiments of dosage test 
Thirty-two rats were randomly assigned into four groups with a B.C. group and 
three groups consisted of 5%, 10% and 20% (w/w) of one mushroom chosen in the 
above screening experiment, respectively. All rats were fed the diets as shown in 
Table 2-1 in 2.1.2.3 ad libitum for four weeks. Fresh diets were given to the animal 
with daily food intake being measured daily, and body weight recorded once a week. 
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2.2.2.1.3 Feeding experiments of solvent extracts from Agrocybe 
aegerita (Brig.) Sing (AA) 
2.2.2.1.3.1 Fractionation of ethanol & water soluble components of 
A A 
Dried and ground AA mushroom powders (252 g) were extracted with absolute 
ethanol (K29955783 146, Merck, Darmstadt, Germany) (three liters) by a glass 
Soxhlet Extraction Apparatus (five liters capacity) for 24 h. Then the ethanol phase 
was concentrated in a Rotary Evaporator (BUCHI Rotavapor R-144, RUCHI 
Labortechnik AG, Switzerland) with the following precautions: 1) Solution volume 
was less than half of the flask volume; 2) The initial rotary speed was 150 rpm with 
gradual acceleration; 3) The vacuum pressure was gradually decreased from 350 mbar 
to 250 mbar; 4) Water bath temperature was kept at 6 0 � C . The ethanol pellet formed 
in the ethanol extract after concentration was homogenized by using a homogenizer 
(Polytron PT-MR 3000, KINEMATICA AG, Switzerland) in order to resuspend it in 
an aqueous solution. On the other hand, the residue from the ethanol extract was dried 
in air, divided into two equal portions, and extracted in hot water (two liters each) in 
two 2L tall-form beakers. The beakers were covered with aluminum foil, and heated 
in a heat plate with temperature control at more than 95°C for 3 h. The volume of 
solutions used for extractions was twenty times the mushroom weight calculated as 
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dry matter. Then the solution was centrifuged 10,000rpm for 30min and the 
supernatant was concentrated in a Rotary Evaporator using similar conditions 
mentioned above (One drop 1- Octanol (Sigma, 0-4500) was added to avoid foam 
forming during the concentration procedures). The final concentrates were then 
freeze-dried and weighed to calculate the yield of the ethanol extract (E.E) and water 
extract (W.E) of AA mushroom. 
2.2.2.1.3.2 Feeding experiments of ethanol & water soluble 
components of A A 
The rats were randomly assigned into three groups with a group size of eight. 
They were Blank Control (B.C) group, Ethanol Extract AA group (E.E) and Water 
Extract AA group (W.E). All of them were fed the diet as shown in Table 2.1 of 
2.1.2.4 ad libitum for three weeks. Each rat of the E.E group and W.E group was 
intragastrically administrated with solutions of the ethanol and hot water extracts of 
AA, respectively, in an equivalent amount of the proportion of each extract present in 
the whole mushroom at 5% of the diet, by weight. The daily oral administration 
volume of each rat was 2 ml (Xu et al., 1982) for 3 weeks. While the rats of B.C 
group were intragastrically administrated with the same volume of distilled water. 
57 
— Chapter Two: Materials and Methods 
2.2.2.1.4 Feeding experiment of long-term test 
The rats were random assigned into two groups with group size of eight. They 
were B.C group and AA supplemented group. They were fed the diets of 2.1.2.5 ad 
libitum for 12 weeks. 
2.2.2.2 Blood sample collection 
At the last day of all the above feeding experiments, at least 5 mi blood samples 
were obtained from the heart of the fasting animals (16-h) after exsanguination under 
light ether narcosis. For long-term test, additional blood samples were drawn monthly 
from the rats' ophthalmic venous plexus by micro hematocrit tubes during the 3 
months' feeding period. 
2.2.2.3 Serum preparation 
After centrifuged at 3000 rpm for 30 min, the upper straw yellow serum phase of 
the blood samples was transferred by a pipette and used immediately or stored at 4°C 
for used within 3 days. 
2.2.2.4 Liver sample preparation 
At the last day of all the feeding experiments, after blood samples were obtained 
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from the fasting rats (16-h) with exsanguinations under light ether narcosis for two to 
three minutes, the livers of the animals were quickly removed, washed with saline (9g 
NaCl/L), blotted dry on filter paper and weighed before freezing in liquid nitrogen 
and then stored in a deep freezer (-70�C). 
2.2.2.5 Fecal sample preparation 
At the end of all the preliminary screening, dosage, and long term experiments 
with four weeks feeding period, all fecal excretion over a 4-d period were collected, 
freeze-dried, milled and kept in desiccator until analysis. While at the end of the 
active ingredient experiment which had three weeks feeding period, all fecal excretion 
over a 3-d period were collected, freeze-dried, milled and kept in desiccator until 
analysis. 
2.2.3 Determination of serum lipid profiles 
2.2.3.1 Serum total cholesterol (TC) assay 
Using total cholesterol (TC) kit (Catalog No.402-20, Sigma), a series of test 
tubes for animal blood specimens (prepared as 2.2.2.2), blank, cholesterol calibrators 
(100 and 200 mg/dL) (Catalog No.C0534, Sigma), and cardiolipid™ control Level 1 
& 2 (Catalog No. C4571 and C4696, respectively, Sigma) were set up. Into each tube, 
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1 ml cholesterol reagent (equilibrated to assay temperature一30�C) as well as 10 |il 
blood specimen, calibrators, controls and blank (deionized water) were added, mixed 
gently, and incubated at 30°C for 10 min. Then the absorbance of the mixture was 
measured at 500nm (within 30 min after the incubation) versus water as reference. 
The TC level in the blood specimen was determined as following: 
TC (mg/dL) = (Atest — Abiank) / (Acaiibrator —Abiank) X Calibrator (mg/dL) 
Where A: absorbance at 500nm. 
2.2.3.2 Serum triglyceride (TG) assay 
Using total triglyceride kit (Catalog No.336, Sigma), a series of test tubes for 
animal blood specimens (prepared as 2.2.2.2), blank, calibrators (250 and 500 mg/dL) 
(Catalog No.T-2772, Sigma), and cardiolipid™ control Level 1 & 2 (Catalog No. 
C4571 and C4696, respectively, Sigma) were set up. Into each tube, 1 ml triglyceride 
reagent (equilibrated to assay temperature—30°C) as well as 10 fil blood specimen, 
calibrators, controls or blank (deionized water) were added, mixed gently, and 
incubated at 30°C for 15 min. Then the absorbance of the mixture was measured at 
500nm (within 30 min after the incubation) versus water as reference. The triglyceride 
level in the blood specimen was determined as following: 
Triglyceride (mg/dL) = (Atest — Abiank) / (Acaiibrator -Abiank) X Calibrator (mg/dL) 
Where A: absorbance at 500nm. 
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2.2.3.3 Serum high-density lipoprotein cholesterol (HDL-c) assay 
2.2.3.3.1 Separation of H D L fraction 
Using HDL-c Reagent [PTA/MgCy (Catalog No.352-4, Sigma), a series of test 
tubes for animal blood specimens (prepared as 2.2.2.2), blank, and cardiolipid™ 
control Level 1 & 2 (Catalog No. C4571 and C4696, respectively, Sigma) were set up. 
Into each tube, 0.1 ml HDL-c Reagent [PTA/MgCy as well as 0.5 ml blood specimen, 
calibrators, and blank (deionized water) were added, vortexed thoroughly, allowed to 
stand at room temperature for 5 min, and centrifuged at 3000rpm for 5 min. Then the 
supematants that contained the HDL-c phases should be transferred to another test 
tube by a pipette as soon as possible. 
2.2.3.3.2 H D L cholesterol (HDL-c) determination 
Using total cholesterol (TC) kit (Catalog No.402-20, Sigma), a series of test 
tubes for animal blood HDL specimens (prepared as 2.2.3.3.1), blank, calibrators (50 
and 100 mg/dL) (Catalog No.H8395, Sigma), and cardiolipid™ control Level 1 & 2 
(Catalog No. C4571 and C4696, respectively, Sigma) were set up. Into each tube, 1 ml 
cholesterol reagent (equilibrated to assay temperature一30�C) as well as 50 fil blood 
specimen, calibrators, controls and blank (deionized water) were added, mixed by 
gentle inversion, and incubated at 30°C for 10 min. Then the absorbance of the 
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mixture was measured at 500nm (within 30 min after the incubation) versus water as 
reference. The HDL-c level in the blood specimen was determined as following: 
HDL-C (mg/dL) = (Atest — Abiank) / (Acaiibmtor -Abiank) X Calibrator (mg/dL) X 1.2 
Where A: absorbance at 500nm. 
Where 1.2: dilution factor of serum when 0.5 ml sample was mixed with 0.1 ml 
HDL-c reagent. 
2.2.4 Determination of liver lipid profiles 
2.2.4.1 Liver total cholesterol (TC) level determination 
According to the method of Folch et al (1957), about 1 g of rat's liver sample 
was homogenized with 20 ml choloroform:methanol mixture (2:1, v/v) at 7000 rpm 
for 2.5 min by using a homogenizer (Polytron PT-MR 3000, Kinematica AG, 
Switzerland). The homogenate was then filtered into a 25 ml volumetric flask, and 
made up to 25 ml with the choloroform:methanol mixture (2:1, v/v). Ten milliliters of 
this mixture was transferred into a 15 ml centrifuge tube into which 2 ml washing 
solutions (calcium chloride solution, 0.05%, w/v) was added and mixed. After 
centrifuged at 3000 g for 10 min, the upper phase was removed as much as possible 
with a pipette. Then, the inside wall of the tube was rinsed with about 1.5 ml 
chloroform:methanol :water mixture (3:48:47, v/v/v) which contained 0.02% (w/v) of 
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calcium chloride, in such as way as not to disturb the lower phase. Next, the tube was 
rotated gently to insure mixing of the rinsing fluid with the remaining original upper 
phase, and then the mixture was removed. This above rinsing of the tube wall and 
interphase with the chloroform:methanol:water (3:48:47, v/v/v) mixture was repeated 
twice. Finally, the remained lower phase was diluted to a volume of 10 ml by adding 
the choloform:methanol mixture (2:1, v/v). 
According to the method of Seary and Bergquist (1960), 0.2 ml of the above 
lipid extract, cholesterol standard*, and blank (choloroform:methanol mixture 2:1, v/v) 
were added into a series of test tubes followed by 3 ml FeSCU-acetic acid solution** 
and 1 ml concentrated sulfuric acid. After standing at RT (20°C) for 10 min, the 
absorbance of the mixture was measured at 490 nm against the blank. 
* Cholesterol standard: forty grams of cholesterol (C-8503, Sigma) were dissolved in 
100 ml choloroform:methanol mixture (2:1, v/v) as stock solution, which was diluted 
to 10 mg/ml for use each time. 
** Saturated FeSCVacetic acid solution: About 3 g of FeSCU • 7 H2O was stirred in 
500 ml acetic acid for 5 min. The mixture was then filtered to obtain a clear saturated 
solution. 
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2.2.4.2 Determination of liver total lipid (TL) level 
Fifteen milliliters of filtered homogenate (unused portion in liver cholesterol 
measurement in 2.2.4.1) was transferred into a preweighed beaker (25ml). The 
organic solvent in the homogenate was evaporated off in ambient temperature 
environment until the weight of the residue left was constant, and the dried beaker 
was weighed to determine the amount of the residual oil (liver total lipid) 
gravimetrically. 
2.2.5 Quantitative determination of fecal neutral & acidic sterols 
According to the method of Chan et al. (1999) with some modification, the fecal 
neutral & acidic sterols were analyzed as following: 
2.2.5.1 Separation of fecal neutral & acidic sterols 
Fifty milligrams of each fecal sample obtained in 2.2.2.5 were used. One 
milliliter of Img/ml stigmasterol (Sigma) in chloroform and 1 ml of 5 mg/ml 
hyodeoxycholic acid (Sigma) in 90% ethanolic IN NaOH were added to the fecal 
sample as the internal standards for neutral and acidic sterols, respectively. Then the 
samples were saponified by adding 8ml 90% ethanolic IN NaOH at 90�C for 1 h. 
After cooling down the samples to room temperature, the extraction was performed by 
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adding 8ml cyclohexane and 1ml dHzO. Then the mixture was centrifuged at 3000 
rpm for ten min. The upper organic layer (cyclohexane) and the lower aqueous layer 
were collected for neutral and acidic sterols analysis, respectively. 
2.2.5.2 Derivatisation of fecal neutral sterols 
The cyclohexane phase was evaporated to dryness by nitrogen gas. TMS-reagent 
(dry pyridine-hexamethyldisilazane-tricholrosilane, 9:3:1, v/v/v, Sil-A reagent, Sigma) 
(0.3 ml) was added and heated at 60°C for 1 h to convert the neutral sterols to their 
corresponding TMS-ether derivatives. The mixture was then evaporated to dryness by 
nitrogen gas and the remained pellet was suspended in 400 jil hexane. After brief 
centrifugation (3000 rpm, 10 min), the clear hexane layer was transferred by a pipette 
to a GC vial for GLC analysis. 
2.2.5.3 Derivatisation of fecal acidic sterols 
One milliliter of 10 N NaOH was added to the remaining aqueous phase and 
heated at 120°C for 3 h. After cooling down the tube to room temperature, one 
mililiter of distilled H2O and 3 ml 25% HCl (v/v, pH<l) were added for neutralization 
of the sample. Then the sample mixture was extracted with 7 ml diethyl ether twice, 
and the phases were separated by centrifugation at 3000 rpm for 10 min. The upper 
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ether phase was evaporated to dryness by nitrogen gas. Methylation was performed by 
adding 2ml methanol, 2 ml dimethoxypropane and 40 \x\ concentrated HCl. Then the 
mixture was vortexed thoroughly and allowed to stand overnight at room temperature. 
After that, the mixture was dried by blowing of nitrogen gas and 0.3 ml TMS-reagent 
(dry pyridine-hexamethyldisilazane-tricholrosilane, 9:3:1, v/v/v, Sil-A reagent, Sigma) 
was added and the mixture was heated at 60°C for 1 h to convert the acidic sterols to 
their corresponding TMS-ether derivatives. Finally the solution was dried down by 
nitrogen gas and the residue was suspended in 600 \Ji\ hexane. After brief 
centrifugation (3000 rpm, 10 min), the suspended hexane phase was further 
centrifuged (10,000 rpm, 5 min), and the clear hexane phase was obtained and 
transferred by a pipettement to a GC vial for GLC analysis. 
2.2.5.4 Gas chromatographic analysis of fecal neutral & acidic sterols 
The GC analysis of fecal neutral and acidic sterols was performed by a fused 
silica capillary column (SUPELCO, SAC-5, 30m X 0.25mm, 0.25|im) in a gas-liquid 
chromatograph (HP6890 Series GC system) equipped with a flame ionization detector. 
For neutral sterols, the column temperature was programmed at 285°C for 30 min. 
Five neutral sterol standards: 1) Coprostanol (C 7578, Sigma); 2) Coprostanone(C 
2152, Sigma); 3) Cholesterol (C 8667, Sigma); 4) Campesterol (C 5157, Sigma); (5) 
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Stigmastanol (S 4297, Sigma) (Internal standard) were used as targets. For acidic 
sterols, the column temperature was programmed at 230�C to 290°C at a rate of 
l�C/min. Six acidic sterol standards: 1) Lithocholic acid (L 6250, Sigma); 2) 
Deoxycholic acid (D 2510, Sigma); 3) Chenodeoxycholic acid (C 9377, Sigma); 4) 
Cholic acid (C 1129, Sigma); 5) Hyodeoxycholic acid (H 3878, Sigma) (Internal 
Standard); 6) Ursodeoxycholic acid (U 5127, Sigma) were used as targets. Helium 
was used as the carrier gas at a constant pressure of 22 psi in both neutral and acidic 
sterols analysis. 
2.2.6 Assays of liver key enzymes in cholesterol metabolism 
2.2.6.1 Preparation of hepatic microsome 
The liver microsomes were isolated according to Erickson et al. (1977) with 
some modifications. In brief, around 2g liver sample taken from a deep freezer (-70 
�C)was homogenized in 8ml ice-cold buffer (pH 7.2), containing 0.1 M sucrose, 0.05 
M KCl，0.03 M EDTA and 0.04 M KH2PO4, using glass homogenizer (fisher, USA) 
with a Telfon pestle. The homogenate was centrifuged twice for 10 min at 12,000 g. 
The upper floating lipid layer was filtered with a piece of pledget and removed after 
each centrifugation, then the supernatant was centrifliged for another 60 min at 
105,000 g. The microsomal pellet from each liver sample was resuspended by gentle 
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homogenization in 2ml of the above buffer with a loose-fitting Teflon pestle, and the 
protein content, which contained the hepatic microsomes, was determined by a protein 
assay kit (P5656, Sigma) that followed the method of Lowry et al (1951). Finally the 
hepatic microsomes were stored in a deep freezer(-70�C) until further analysis. 
2.2.6.2 Assay of H M G - C o A reductase activity 
HMG-CoA reductase activity was analyzed according to Shapiro et al. (1974) 
and Lee et al. (1999) with some modifications. Briefly, for each sample essay, 400 |ig 
microsomal protein homogenate was mixed with assay buffer (pH 7.2), containing 54 
mM dithiothreitol (DTT) (D 9779, Sigma), and 16 mM NADPH (N 1630, Sigma). 
The mixture was pre-incubated at 37°C with gentle shaking for 20 min. Then the 
reaction was carried out by addition of 10 }il DL-3-[glutaryl-3- ^ "^ C]- HMG-CoA 
(NEC-642, PerkinElmer) and cold HMG-CoA (H 6132, Sigma) mixture (279 i^l 
DL-3-[gliitaryl-3-i4c]- HMG-CoA and 5mg cold HMG-CoA powder dissolved in the 
assay buffer to a final volume of 1ml) to ICi/mol. Then the sample mixture was 
incubated at 37�C with gentle shaking for 60 min. Twenty microliters of 5N HCl was 
added to terminate the reaction and 10 |il RS-[5-^H(N)]- mevalonolactone (NET-602, 
PerkinElmer) (1 mCi/ml) was then added as the internal standard. The final mixture 
was incubated at 37�C with gentle shaking for a further 30 min to let the mevalonate 
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transfer to mevalonolactone. Then the precipitated protein of the sample assay was 
removed by centrifugation (10,000 rpm, 10 min) and the supernatant was applied to a 
TLC plate (Silica gel/TLC-cards, DC-Alufolien-Kieselgel, Fluka). Pure ethanol was 
used for TLC development and 2',7'-dichlorofluorescein (D 6665, Sigma) (0.2%) in 
ethanol was used as dye. The band corresponding to [ � � C ] mevalonolactone was 
scraped and added into liquid scintillation fluid for scintillation counting while using 
dpm as radioactivity unit. Time-zero assay was performed as a background value and 
used in the enzyme activity calculation. One unit of HMG-CoA Reductase activity 
was defined as one pmol/hr/mg protein (pmol: the amount of [^ "^ C] mevalonolactone) 
calculated by the below formula: 
Enzyme activity = [(Rsampie - Rbiank) (dpm) X factor 1] / [factor 2 (dpm/mol) / reaction 
time (hr) / microsome protein (mg)] 
Where R: radioactivity measured by scintillation counter 
Where factor 1: correction factor for the recovery of RS-[5-3H(N)]- mevalonolactone 
which was used as internal standard to measure the loss during TLC procedure. 
Where factor 2: the relationship between mole and radioactivity of mevalonolactone. 
2.2.6.3 Assay of C Y P 7 A activity 
The activity of hepatic CYP7A was determinated according to Souidi et al (1998) 
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with some modifications. In brief, the exogenous cholesterol substrates were prepared 
as follows: [4-14c] cholesterol (NEC-018, PerkinElmer) (160 nmol) was dissolved in 
ethanol and mixed with Tween 80 (P 1754, Sigma) (12.5 mg). After the ethanol had 
been evaporated in air, the substrate was mixed with 4ml homogenization buffer 
(prepared as 2.2.6.1), then sonicated for 1 min for thorough mixing. This substrate 
solution (250 jil) contained 0.1 ^imol cholesterol [0.01 |imol [4- '^^ C] cholesterol and 
0.09 jimol cold cholesterol (C 8667, Sigma)] (1.1 X 10^ dpm) and 0.78mg Tween 80. 
Then the following chemicals were added to each assay tube with 500 jil assay 
solution to determine the CYP7A activity of rat hepatic microsomes: EDTA (1 
mmol/1), DTT (0.5 mmol/1), MgCls (5 mmol/1)，NADPH (2 mmol/1), 
[4-i4c]cholesterol (52 |imol/l, 1.1 X 10^ dpm), phosphate buffer (75 mmol/1), Tween 
80 (0.78 mg) and liver microsomal protein (250 |ig). Then the contents of the assay 
tubes were mixed and preincubated at 37°C in a shaking water bath for 5 min without 
NADPH. Then NADPH (150 |il) was added to initiate the reaction in the assay tubes 
for 6 min before terminated by adding 40 [i\ 5N NaOH. Time-zero sample as blank 
control of each liver microsome sample was run in parallel by the additon of 5N 
NaOH at the beginning of the preincubation period. After neutralization by adding 5N 
HCl, the sterols were extracted with 5 ml chloroform-methanol solution (v/v: 2:1) and 
1 ml saline (9g NaCl/L). Then the [^ "^ C]? a -hydroxycholesterol within the enzyme 
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product was separated by TLC plate (Silica gel/TLC-cards, DC-Alufolien-Kieselgel, 
Fluka). Diethyl ether was used for the TLC development with 
2',7'-dichlorofluorescein (0.2%) in ethanol was used as dye. The band corresponding 
to 7 a -hydroxycholesterol was scraped and added into liquid scintillation fluid for 
scintillation counting. One unit of CYP7A activity was defined as one pmol/min/mg 
protein calculated by the same formula as 2.2.7.2, except that the substrate 
(cholesterol) was used directly to estimate TLC plate recovery rate. 
2.3 Data statistics 
All analyses were performed in duplicate except the determination of fecal 
sterols by GLC in single. The data were recorded as means 士 standard errors. The data 
obtained were analyzed by SigmaStat for Windows Version 2.03 (SPSS Inc.) and 
SigmaPlot 2001 for Windows Version 7.0 (SPSS Inc.). One-way analysis of variance 
(ANOVA) and Tukey multiple comparisons were carried out to detect for any 
significant differences between means. The mean values of mushroom sample groups 
and the blank control groups were analyzed by student t-test. Differences between 
means at 5% level with p<0.05 were considered significant. Correlations were 
obtained by Linear Regression Analysis and considered significant & confident when 
p < 0 . 0 5 . 
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Chapter Three: Results and discussion 
3.1 Preliminary screening of eleven mushrooms for their 
hypolipidemic effect in hyperlipidemic S.D. rats 
The aim of the experiments in this stage is to screen the potential hypolipidemic 
mushrooms from some edible and medicinal oriental mushroom species for further 
investigation. Eleven fungi were chosen based on three criteria: 1) By their different 
predominant nutritional components. Since dietary fiber (Cheung, 1996a) and protein 
(Potter, 1995) are believed to be the effective agents in functional food with 
hypolipidemic effect, so the content of TDF and protein was the primary 
consideration. For instance, sclerotia of PTR, PR and PC had very high TDF content 
90%), as well as AB had high crude protein content (27.3%) (Wong, 2002); 2) By 
referring to the literature, Pleurotus mushrooms had pronounced potent lipid-
lowering effect (Bobek et al., 1994a, 1994b). Therefore, some Pleurotus species such 
as PEVN and PE were chosen; 3) Some of the chosen mushrooms like AA, CC, are 
newly cultivated with potential commercial value and they have not been studied 
previously. 
Five percent (w/w) mushroom dry powder, replacing the same amount of 
cornstarch, with 2% cholesterol was added in an AIN-93M diet and used to feed male 
adult S.D. rats for four weeks (2.1.2.2). Then the serum blood lipid profiles, hepatic 
lipid profiles and fecal neutral sterol excretion were analyzed. In practice, all of the 
eleven mushrooms groups were divided into 3 batches each with a blank control (B.C.) 
group, and a positive control (whole oat) group was used in the batch for 
comparison (2.2.2.1.1). 
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3.1.1 Body weight and food intake 
In the first batch of the screening experiments, there was no significant 
difference in food intake (g/d) and body weight gain (g/d) between the mushroom 
groups and the control group (Table 3-1), though there was a significant difference 
between PEVN and PR groups. 
In the second batch of the screening experiments, the food intake was varied 
slightly between each mushroom group and the control group without any statistical 
significant difference. However, the body weight gain in the HE and AC diet groups 
was decreased significantly by 12.6% and 13.9%, respectively as compared with the 
control group (Table 3-2). 
In the third batch of the screening experiments, the food intake of PTR group 
was significantly increased by 12.5% as compared to the B.C. group. Furthermore, the 
body weight gain in CC group was significantly increased by 12.7% as compared to 
that of control group (Table 3-3). 
In the four-week feeding periods with the hypercholesterolemic diet, there was 
no significant difference in the daily food intake amount between the M.S. group and 
the B.C group. However, there was a significant reduction in the rate of body weight 
gain occurred in the HE and AC groups as compared to the control group, which 
might be due to the lower crude protein content and unbalanced amino acid profiles in 
these two mushrooms (Wong, 2002). 
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Table 3-1 The food intake and body weight of S.D. rats in the 
ist screening experiments 
Diet Food intake (g/day/rat) Body weight gain (g/day) 
B . C . 2 7 . 0 ± 0 . 3 5 6.47士0.13 A，B 
PEVN 26.3±0.28 ^ 6.31±0.13 ^ 
PE 27.1±0.19a，b 6.70±0.14a，b 
AA 27.6±0.53a，b 6.43±0.12''^ 
PR 27.8±0.15 b 6.75±0.12 ^ 
Data are expressed as mean 士 SE, n=8. 
Values in the same column with different superscripts (a, b) are significantly 
different between groups. (ANOVA, Tukey, P<0.05) 
Table 3-2 The food intake and body weight of S.D. rats in the 
2nd sc reen ing e x p e r i m e n t s 
Diet Food intake (g/day/rat) Body weight gain (g/day) 
B.C. 28.1 士0.53 a，b 8.00±0.14" 
AB 27.0±0.39 ‘ 7.78士0.16 a 
PC 29.1±0.42 b 
HE 26.2士0.60 ‘ 6.99士0.20 b 
OAT 27.2±0.36"山 8.34±0.17' 
AC 27.1 士0.08 a，b 6.89士0.09 b 
Data are expressed as mean 士 SE, n=8. 
Values in the same column with different superscripts (a, b) are significantly 
different between groups. (ANOVA, Tukey, P<0.05) 
Table 3-3 The food intake and body weight of S.D. rats in the 
3rd sc reen ing expe r imen t s 
Diet Food intake (g/day/rat) Body weight gain (g/day) 
B.C. 26.5士0.72 ‘ 6.20士0.23 ‘山 
PTR 29.8±0.72 b 6.68士0.15 a，e 
CC 28.1±0.40a，b 6.99±0.13 ‘ 
LG 26.8±1.81''^ 5.73±0.23 ^ 
Data are expressed as mean 士 SE, n二8. 
Values in the same column with different superscripts (a, b and c) are 
significantly different between groups. (ANOVA, Tukey, P<0.05) 
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3.1.2 Effect of mushroom supplementation on serum lipid profiles 
3.1.2.1. Effect of mushroom supplementation on serum T C levels 
In the first batch of screening experiments, fasting serum total cholesterol (TC) 
level was decreased in all mushroom diet groups compared to control group but 
significant difference was only found in the AA group: PEVN (-21.1%) (P=0.123); 
PE (-18.2%) (P-0.134); AA (-38.1%) (P=0.007) and PR (-5.6%) (Figure 3-1). 
In the second batch of screening experiments, the fasting serum TC level was 
greatly reduced in the OAT group by 16.4% without statistical significance 
(P=0.171), similarly no significant difference between control and other mushroom 
groups was found (Figure 3-2). 
In the third batch of screening experiments, there was a slightly non-significant 
increase in the fasting serum TC in the mushroom groups as compared to B.C. group 
(Figure 3-3). 
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Figure 3-1 Serum total cholesterol (TC) level of S.D. rats in 
batch mushroom screening experiments 
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Figure 3-2 Serum total cholesterol (TC) level of S.D. rats in 
batch mushroom screening experiments 
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Figure 3-3 Serum total cholesterol (TC) level of S.D. rats in 
3rd batch mushroom screening experiments 
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3.1.2.2. Effect of mushroom supplementation on serum T G levels 
In the first batch of screening experiments, similar to the serum TC level, 
fasting serum triglyceride (TG) level was decreased in all mushroom supplemented 
groups compared to the control group but only the AA group had significant 
difference: PEVN (-2.90%); PE (-22.7%) (P=0.172); AA (-29.3%) (P=0.041) and PR 
(-14.5%) (P-0.602) (Figure 3-4). 
In the second batch of screening experiments, as compared to the control group, 
the fasting serum TG level was significantly increased in the HE group by a 
surprisingly 74.6% (P<0.01) for unknown reason. However, there was no significant 
difference between the control and the other mushroom groups (Figure 3-5). 
In the third batch of screening experiment, similar to the serum TC level, the 
fasting serum TG level of PTR, CC and LG groups was 51.0 (mg/dL), 57.5(mg/dL), 
and 47.9 (mg/dL), respectively. All of them were slightly higher than that of the 
control group 48.0 (mg/dL), though not statistically significant. 
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Figure 3-4 Serum triglyceride (TG) level of S.D. rats in 
batch mushroom screening experiments 
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Figure 3-5 Serum triglyceride (TG) level of S.D. rats in 
batch mushroom screening experiments 
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3.1.2.3. Effect of mushroom supplementation on serum H D L levels 
In the first batch of the screening experiments, there was not any significant 
difference between fasting serum HDL level of the mushroom diet groups and the 
control group (Figure 3-6A). However, the HDL to TC ratio of the PEVN, PE and 
AA groups was enhanced by 8.77% (P=0.977), 17.5% (P-0.032) and 59.6% 
(P<0.001) compared to the control group (Figure 3-6B). Furthermore, "Atherogenic 
index", a positive parameter to the risk of atherogenesis, indicated by the non-HDL 
to HDL ratio [(TC-HDL) / HDL], of the AA group was significantly lowered to only 
ten percent of that of the control group, while that of PEVN and PE groups were 
(74.0%) (P=0.392) and (63.5%) (P=0.243), respectively (Figure 3-6C). 
In the second batch of the screening experiments, AC group had a significant 
reduction in the serum HDL concentration by 29.6% (P=0.024) compared to the 
control group (Figure 3-7A), while the decrease of serum HDL level in the OAT 
(23.9%) (P-0.106), AB (15.3%) (P-0.541) and HE group (13.6%) (P=0.657) were not 
significant. About the HDL/TC ratio, there was a slight reduction between all five 
mushroom groups and the control group, with the AC group having a significant 
decrease (P<0.05) (Figure 3-7B). As to the Athero. Index, all five mushroom groups 
had a larger value than the control group, with AC group having the largest Athero. 
Index which was 2.5 times of that in the control group (Figure 3-7C). 
In the third batch of the screening experiments, there was only a slight reduction 
in the serum HDL concentration between PTR (14.6%) (P-0.124), CC (5.81%), LG 
(14.0%) (0.136) and the B.C. group (Figure 3-8A). Furthermore, the HDL/TC ratio of 
the three mushroom groups was lower than that of the B.C. group but the difference 
was not significant (Figure 3-8B). Accordingly, all the mushroom groups showed a 
higher Athero. Index than B.C. group without significant difference (Figure 3-8C). 
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Figure 3-6 
Serum H D L cholesterol level (3-6A)，HDL/TC ratio (3-6B) and 
Athero. Index (3-6C) of S.D. rats in the batch screening 
experiments 
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Figure 3-7 
Serum H D L cholesterol level (3-7A)，HDL/TC ratio (3-7B) and 
Athero. Index (3-7C) of S.D. rats in the batch screening 
experiments 
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Figure 3-8 
Serum H D L cholesterol level (3-8A), HDL/TC ratio (3-8B) and 
Athero. Index (3-8C) of S.D. rats in the batch screening 
experiments 
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3.1.2.4 Discussion of serum lipid profiles of S.D. rats fed M.S. diets in 
mushroom screening experiments 
Among the eleven mushroom samples, AA, PE and PEVN supplementations 
(constituted 5% dried mushroom powder in diet) could greatly lower the serum TC by 
38.1%, 18.2%, 21.1% and TG level by 29.3%, 22.7%, 2.9%, respectively in S.D. rats 
fed with a high cholesterol diet. Furthermore, all of the three mushroom 
supplementations had no significant effect on serum HDL cholesterol, which could 
also be implied by the enhanced HDL/TC ratio and decreased Athero. Index (non 
HDL/HDL ratio) of these mushroom groups as compared to the B.C. group. LDL and 
HDL are well known as the two major lipoproteins to transport most of the cholesterol 
in blood (Fielding, 2000), Therefore, the above results indicated that the serum lipid 
lowering effect of the mushrooms might be mainly due to the reduction of the serum 
LDL cholesterol level. Bobek and his colleagures (1993) found that the oyster 
mushroom and its water extract significantly decreased the rats' serum TC level when 
supplemented in a high fat diet, while the LDL cholesterol reduction accounted for the 
predominant hypolipidemic effect. 
Furthermore, the LDL cholesterol lowering effect of AA mushroom diet might 
be partly due to AA's possible antioxidant function (Lo, 2003). The cellular LDL 
receptors cannot distinguish the oxidative LDL, which are known to be the key event 
in the initiation and progression of atherosclerosis (Steinberg et al., 1989). AA can 
inhibit the LDL oxidation, making more LDL cholesterol being transferred 
intracellularly (especially in liver), which accounts for a reduction of serum LDL 
cholesterol and TC levels. 
Also, in the gene transcription level, another hypothesis on serum LDL 
cholesterol lowering effect relies on the regulation of hepatic LDL receptor mRNA 
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level, which negatively correlated with the serum VLDL + IDL + LDL cholesterol 
concentrations. It had been found that the mushroom fiber of Flammulina velutipes 
and Agaricus bisporus significantly decreased the serum TC & LDL cholesterol levels 
in normolipic rats by mean of increasing the hepatic LDL receptor mRNA level 
(Fukushima et al, 2000, 2001). 
Finally, the activity of a key enzyme LCAT, converting serum free cholesterol to 
HDL cholesterol (as refer to 1.1.4), was significantly increased by 13% in rats fed 
with oyster mushroom supplementation diet as compared to a blank control diet 
(Bobek et al.，1994c), which might be another possible explanation on AA 
supplemented diet maintaining a constant HDL level as well as an corresponding 
significant decrease in serum TC level. 
3.1.3 Effect and discussion of mushroom supplementation on hepatic 
lipid profiles 
Based on the above results of the serum lipid profiles in the eleven M.S. groups, 
three mushroom supplementation groups PE, PEVN and AA which showed the higher 
potent hypolipidemic effect than the other mushroom species, were selected for 
further analysis of their effect on the hepatic lipid profiles of the rats fed with high 
cholesterol diets. 
The hepatic total lipid level (mg/ g liver) of PE, and AA was greatly decreased 
significantly as compared to the control group by 15.0%, and 32.0% respectively with 
a corresponding P value of 0.004, and less than 0.001 (Figure 3-9). 
Similarly, the hepatic total cholesterol level (mg/g liver) was also decreased 
significantly in the PE (20.5%) and AA groups (38.5%) compared to that of control 
group, with the P value of 0.002 and ^0.001, respectively (Figure 3-10). 
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Figure 3-9 
Hepatic total lipid level (mg/g liver) of S.D. rats in the mushroom 
screening experiments 
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Figure 3-10 
Hepatic total cholesterol level of S.D. rats (mg/g liver) in the 
mushroom screening experiments 
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All of the above data indicated that besides the two Pleurotus species PE and 
PEVN, a lesser-known oriental edible mushroom~Agrocybe aegerita (Brig.) Sing 
(AA), had the strongest inhibitory effect of lipid accumulation in liver. A similar 
result was found in the supplementation of Maitake fruit body {Grifola frondosa), 
which significantly decreased the weight of liver and epididymal fat-pads by 31.9 % 
and 37.1%, respectively as compared to the control group of S.D. rats (Kubo and 
Nanba, 1997). One of the possible explanations of AA's hypolipidemic effect on 
hepatic lipid profiles is the suppression of the de novo cholesterol synthesis in liver, 
especially by inhibiting the activity of HMG-CoA reductase, a rate-limiting enzyme 
that catalyzes the endogenous cholesterol biosynthesis (Retey et al., 1970). The 
testing of this explanation will be described later (as refer to 3.3.5.2). 
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3.1.4 Effect and discussion of mushroom supplementation on fecal 
neutral sterol excretion 
The fecal samples of the PEVN, PE and AA diet groups in the last four days 
during the 4 wk feeding period were collected for the analysis of the neutral sterol 
composition. The weight of the daily feces excretion by the rats of the PEVN and AA 
groups was significantly larger than that of control group (P<0.001) (Table 3-4). 
During the GLC analysis of fecal neutral sterols, five neutral sterols were added as 
standards with Stigmastanol as the internal standard (Figure 3-11). Three neutral 
sterols, coprostanol, cholesterol and campesterol were detected by GLC analysis in 
the rat fecal samples, with cholesterol being the dominant component ( ^ 96%) (Data 
not shown). Furthermore, in the PE group, the excretion of cholesterol was 
significantly decreased by 21.9% (P<0.05) compared to the control group, making it 
the only mushroom group that had a significant lower fecal total neutral sterol 
excretion (-20.6%) (P<0.05) than the control group (Table 3-4). 
Table 3-4 
The fecal neutral sterol excretion of S.D. rats in some selected 
mushroom supplemented groups in screening experiments 
Feces weight Fecal neutral sterols (mg/day) 
(g/day) coprostanol cholesterol campesterol Total 
B.C. 2.61 士0.05 a 5 . 4 1 ± 1 . 0 5 ^ 408士9.40 ^ 5.41±0.14^ 418±9.69' 
PEVN 3.12士0.06 b 9.94士0.72 B 391 士9.76 A 5.72土0.15 A 4 0 6 ± 1 0 . 4 " 
PE 2.74±0.11 ^ 8.40±1.14a 318±12.84^ 5.62+0.26" 332±12.8 ^ 
AA 3.10±0.08^ 11.9±1.52^ 398±9.63 ‘ 6.54±0.21 ^ 416士 10.6" 
Data are expressed as mean 士 SE, n=8. 
Values in the same column with different superscripts (a, b) are significantly different 
between groups (ANOVA, Tukey, P<0.05). 
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Gas-liquid chromatography of fecal neutral sterol standards: 





(5) Stigmastanol (Internal standard). 
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One possible hypolipidemic mechanisms may be due to the acceleration of 
cholesterol metabolism and the increased excretion of fecal neutral & acidic sterols 
(Cheung, 1996a). However, the present data showed that the fecal neutral sterol 
output in the mushroom groups was not significantly higher than the control group, 
and there was even a significant lower fecal neutral sterol output in the PE diet group 
as compared to the control group. This might be explained by two possible reasons: 1) 
In this experiment, the fecal samples were all collected in the last four days of the 
one-month feeding period, during which, the total lipid pool (including serum TC, TG, 
hepatic TL, TC) had already been reduced significantly in the PEVN, PE and AA 
groups as compared to B.C. group. A significant enhancement of fecal neutral sterol 
excretion might have been already occurred before the feces collection period. This 
hypothesis was supported by a previous in vivo study of Maitake mushroom 
supplementation diets (Kubo and Nanba, 1997). In that study, the cholesterol 
excretion rate, which was determined by measuring total cholesterol content ingested 
in food versus that excreted in feces, was increased by 1.8 times on the day in 
maitake mushroom diet group as compared to control group. But in the day, the 
increase of the ratio diminished to no more than 20%; meanwhile, the fecal acidic 
sterol excretion of maitake mushroom diet group was 3 times higher than that in 
control group. These results suggested that the hypolipidemic effect might be due to 
the acceleration of the cholesterol excretion in the early stage of mushroom diet 
feeding and increased the catabolism of cholesterol to bile acids and its fecal excretion 
in the later stage. The following investigations of the determination of fecal acidic 
sterols excretion in AA mushroom diet groups would be used to confirm this 
hypothesis (3.2.5). 2) The enhancement of fecal neutral sterol output was not likely 
necessarily be responsible for the hypocholesterolemic effect of PEVN, PE, and AA 
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mushrooms. It had been found that the tangerine-peel extract had a potent plasma and 
hepatic lipid lowering effect in chow-induced hypercholesterolemic rats, but the fecal 
neutral sterol excretion of the treatment group was decreased by 60% compared to 
that in control group (Bok et al., 1999). Therefore, a decrease in the fecal sterol 
excretion could also be found when hypolipidemic effect was observed because other 
possible alternative mechanisms existed. As mentioned in 3.1.3, another 
hypocholesterolemic mechanism is the suppression of the endogenous cholesterol 
synthesis, especially by inhibiting the activity of HMG-CoA reductase, a rate-limiting 
enzyme that catalyzes the cholesterol biosynthesis (Retey et al., 1970). In addition, 
the suppression of the activity of Acyl-CoA-cholesterol acyltransferase (ACAT) (EC 
2.3.1.26) is believed to decrease the cholesterol absorption and esterification in the 
intestine, leading to a reduction of body sterol pool (Zhang et al., 2002a, 2002b). 
3.1.5 Summary (mushroom screening experiments) 
Among the eleven edible and medicinal mushrooms, beside two Pleurotus 
species: PEVN and PE, a lesser-known oriental edible mushroomAgrocybe aegerita 
(Brig.) Sing (AA) was a potential hypolipidemic agent with the strongest lowering 
effects on serum and hepatic lipid levels. The lipid level lowering effect of AA 
mushroom as compared to B.C. group were summarized as: 1) serum TC level 
decreased by 38.1% (P=0.007); 2) serum TG level decreased by 29.3% (P=0.041); 3) 
hepatic TL level decreased by 32.0% (PS0.001); 4) hepatic TC level decreased by 
38.5% (P^O.OOl). Meanwhile, the fecal neutral sterol excretion of PEVN, PE, and 
AA diet groups were not significantly increased as compared to that of control group. 
Hence, further investigations including the effect of dosage, hypolipidemic active 
fractions in AA as well as long-term feeding and the possible hypolipidemic 
mechanisms of AA mushroom were carried out. 
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3.2 Hypolipidemic effect of Agrocybe aegerita (Brig.) Sing (AA) in a 
dose-response study in hyperlipidemic S.D. rats 
Different amounts of AA dry powder (5%, 10% and 20%) were added in a 
hypercholesterolemic diet and used to feed male adult S.D. rats with a B.C. group for 
four weeks. Since the nutritional components of AA had been analyzed, so the added 
mushroom dry powder not only substituted the cornstarch portion, but also casein and 
cellulose in proportions, to form an isocaloric diet compared to the B.C. group (Table 
2-1). 
3.2.1 Nutritional composition of A A mushroom 
The major nutritional composition of AA was analyzed which included: crude 
protein (23.61%), total dietary fiber (TDF) (30.48%), crude lipid (2.54%), ash 
(6.97%), moisture (6.97%), and carbohydrate (29.40%) {calculated by difference). 
3.2.2 Body weight and food intake 
In the daily food intake, there was not any significant difference between the 
three AA groups and the B.C. group, except a significant difference existed between 
the 5% AA group and 10% AA group (Table 3-5). However, an inverse relationship 
between the amount of mushroom supplement and the net body weight gain was 
observed (Table 3-5). All AA diet groups had significantly lesser body weight gain 
than the control group. The body weight gain in the 5%, 10%, and 20% AA diet 
groups was 88.2%, 83.5% and 52.9% as compared to that of the B.C. group (Table 3-
5). 
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Table 3-5 
The food intake and body weight gain of S.D. rats in dose-response 
study of A A diets 
Diet Food intake (g/day/rat) Body weight gain (g/day) 
B Z 24.8±1.07 7.35±0.23 ‘ 
5% AA 23.5±0.74 ‘ 6.48士0.24 ^ 
10% AA 27.3±0.62 ^ 6.14±0.16^'' 
20% AA 26.0±2.02a’b 3.89±0.14 ^ 
Data are expressed as mean 士 SE (n=8). 
Values in the same column with different superscripts (a, b, c, and d) are 
significantly different between groups (ANOVA, Tukey, P<0.05). 
Although the daily food intake was similar in all groups, the rate of body weight 
gain of rats was much slower in the AA supplemented groups than the control group, 
especially in the 20% AA group. Firstly, it may be due to the fact that the protein in 
AA had an unbalanced amino acid profile, resulting in a lower energy and protein 
digestibility than the casein (milk protein) in the control group (Wong, 2002). 
Secondly, the potential toxicity of the AA mushroom due to such a high dose 
supplementation (20%, w/w) was also possible. Thirdly, the reduction of body total 
lipid accumulation might lead to a lower energy pool which negatively affect the 
growth of the animals. For instant, a similar significant body weight lowering effect 
was observed in maitake mushroom {Grifola frondosa), of which 20% dry mushroom 
powder supplementation significantly decreased the serum TG, phospholipid level, 
liver and epididymal fat-pads weight in chow-induced hyperlipidemic rats (Kubo and 
Nanba, 1997). 
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3.2.3 Effect of three different dosages of A A mushroom 
supplementation on blood lipid profiles of S.D. rats 
3.2.3.1 Effect of different dosages of A A mushroom supplementation 
diets on serum T C level 
Thirty-two male S.D. rats were assigned randomly in four groups of eight 
animals each. The mean baseline serum TC level in each group was found to be 84.0 
士 3.68 (SE) (mg/dL). After 4 weeks feeding, fasting serum TC level of the B.C group 
was increased by 18.7% compared to the baseline value, while that of 5%, 10% and 
20% AA groups was significantly decreased by 21.2%, 26.8% and 26.7%, 
respectively (Figure 3-12). 
Moreover, there was also a significant reduction (P<0.001) of fasting serum TC 
level between the AA groups and the B.C group (Figure 3-12), as well as no 
significant difference among the three AA groups. 
3.2.3.2 Effect of different dosages of A A mushroom supplementation 
diets on serum T G level 
Although the fasting serum TG level of three AA groups was enhanced 
compared to the control group, only the 10% AA group had a significant different in 
TG level (32.5%) (Figure 3-13). 
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Figure 3-12 
Fasting serum T C level in S.D. rats fed A A supplementation diets 
with three different dosages 
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Figure 3-13 
Fasting serum T G level in S.D. rats fed A A supplementation diets 
with three different dosages 
94 
__ Chapter Three: Results and discussion 
3.2.3.3 Effect of different dosages of A A mushroom supplementation 
diets on serum H D L level 
Similar to that of serum TC level, all three AA groups lowered the fasting semm 
HDL level compared to the control group by 28.0% (P<0.001), 22.5% (P=0.002) and 
11.40/0 (P=0.199), respectively. Besides, there was also a significant decrease in serum 
HDL level between the 5% AA group and the 20% AA group (Figure 3-14A). 
The 5%, 10% and 20% AA groups all greatly increased the HDL/TC ratio 
compared to B.C. group by 10.7%, 26.8% and 41.7% (PO.Ol) (Figure 3-14B). 
Moreover, there was a significant positive correlation between the percentage of AA 
mushroom supplemented in the diet and the HDL/TC ratio shown by linear regression 
analysis (R=0.987; PO.OOl) (Figure 3-14B). 
On the contrary, all AA groups had a dramatic decrease in the Athero. Index by 
17.6%, 45.90/0 and 64.7% (PO.Ol), respectively, as compared to that of B.C. group 
(Figure 3-14C). There was a significant negative correlation between the amount of 
AA mushroom supplement and the Athero. Index shown by linear regression analysis 
(R-0.976; P=0.004) (Figure 3-14C). 
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Figure 3-14 
Fasting serum H D L levels (3-14A), HDL/TC ratio (3-14B), and 
Athero. Index (3-14C) in S.D. rats fed A A supplementation diets with 
three different dosages 
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3.2.3.4. Discussion of different dosages of A A mushroom 
supplementation diets on serum lipid profiles 
From the serum lipid profiles, we found that all the three AA groups with 
different dosages significantly lowered the serum TC level compared to that of control 
group, and there was no significant difference between the three AA groups. It 
seemed that the amount of 5% AA in the diet was sufficient to reduce the serum TC 
level to a significant extent, and further increase in AA % in the diet did not result in a 
higher hypolipidemic activity in the rats. However, the TG level of the three A A 
groups was slightly higher than that of control group, which was not consistent with 
the previous results in the mushroom screening experiments (3.1.2). At present, a 
constant relationship between the TG lowering effect and dietary % AA in diet was 
not observed. So far it could not be confirmed that AA has a hypotriglyceridemic 
effect in a short term (4 wk) period and more data in future studies are required. 
Besides, the serum HDL level of the three AA groups was lower than the control 
group, probably due to the reduction of the total cholesterol pool in the blood 
circulation. However, a significant positive correlation was found between the AA 
dosage and the HDL/TC ratio. A significant negative correlation was also found 
between the Athero.Index (non-HDL/HDL ratio)—a good indicator of the degree of 
atherosclerosis (Lee et al., 1999)—and the AA dosage. Thus, AA supplementation 
seemed to have an effective protection of the animals from development of 
atherosclerosis, and the higher AA % in the diets, the better the protective effect. Also, 
it seemed that the serum lipid lowering effect of AA was attributed to the LDL 
cholesterol level reduction with a dose-response correlation (as refer to 3.1.2.4). 
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3.2.4 Effect and discussion of three different dosages of A A 
mushroom supplementation on hepatic lipid profiles 
The hepatic Total lipid (TL) level in the 5%, 10%, and 20% AA groups was 
significantly reduced by 28.5%, 34.9% and 41.6% (P<0.001), respectively, as 
compared to B.C. group (Figure 3-15). 
Similarly, the hepatic TC level of the 5%, 10%, and 20% AA groups was 
significantly reduced by 56.0%, 58.8% and 76.5% (PO.OOl), respectively, as 
compared to B.C. group (Figure 3-16). 
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Figure 3-15 
Hepatic Total lipid level (mg/g liver) in rats fed A A 
supplementation diets with three different dosages 
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Figure 3-16 
Hepatic Total cholesterol level (mg/g liver) in rats fed A A 
supplementation diets with three different dosages 
Consistent with the previous results of mushroom screening, the present data 
on hepatic TL and TC levels indicated a significant progressive decrease in all AA 
groups, with the lowest level being found in the 20% AA group. This showed that AA 
supplementation effectively inhibited the lipid accumulation in the rat's liver. This 
could also be supported by the appearance of the rats' livers (Figure 3-17). The livers 
in some rats of the control group were considerably swollen with pall yellow color 
and luster turning into those of fatty livers, while these features were not observed in 
the AA group (Figure 3-17). 
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Figure 3-17 
Appearance of liver removed from S.D. rats fed the 5 % A A diet as 
compared to the B.C. diet 
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3.2.5 Effect and discussion of three different dosages of A A 
mushroom supplementation on fecal neutral & acidic sterol excretion 
As mentioned previously (3.1.4), neutral sterols were used as the standards with 
the Stigmastanol as the internal standard (Figure 3-18). In this investigation, three 
neutral sterols, coprostanol, cholesterol and campesterol were detected by GLC 
analysis from the rat fecal samples, with cholesterol being the major component 
97%) (data not shown). 
The content of fecal neutral sterols in all of the three AA groups was decreased 
as compared to the B.C. group, with the 20% AA group having the lowest value ( P ^ 
0.001) (Table 3-6). 
On the other hand, six acidic sterols were used as the standards with the 
hyodeoxycholic acid as the internal standard (Figure 3-18). The total amount of the 
fecal acidic sterols in the three AA groups and the control group was similar except 
that there was a significant decrease of fecal acidic sterols in the 20% AA group 
compared to that of 10% AA group (P<0.01) (Table 3-7). 
All in all, the fecal total sterols of the 5% and 10% AA groups were only slightly 
reduced in comparison with the control group, while that of the 20% AA group was 
significantly decreased by 25.1% (P=0.009) (Table 3-7). 
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Figure 3-18 
Gas-liquid chromatography of fecal acidic sterols standards 
The peaks are the TMS-ether derivatives of following acidic sterols: 
1) Lithocholic acid; 
2) Deoxycholic acid; 
3) Chenodeoxycholic acid; 
4) Cholic acid; 
5) Hyodeoxycholic acid (Internal Standard); 
6) Ursodeoxycholic acid. 
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Table 3-6 
The fecal neutral sterol excretion in S.D. rats fed A A 
supplementation diet with three different dosages 
Fecal neutral sterols (mg/day) 
Diets 
Coprostanol Cholesterol Campesterol Total 
B Z 7.27士0.95 a 448士 14.8 ^ 5.70士0.40 461±19.7^ 
5 % A A 1 1 . 7 ± 1 . 1 2 B 427士 12.9 A 5 . 8 7 ± 0 . 2 7 ^ 4 4 4 ± 1 3 . 0 A 
10% AA 5.40±1.29 ^ 420±7.62 ^ 5.75±0.21 432士8.93 ‘ 
2 0 % A A 5.10士0.62 A 3 3 8 ± 1 1 . 5 B 5 . 0 5 ± 0 . 2 8 ^ 3 4 3 ± 1 1 . 1 B 
Data are expressed as mean 士 SE (n=8). 
Values in the same column with different superscripts (a, b) are significantly different 
between groups (ANOVA, Tukey, P<0.05). 
Table 3-7 
The fecal acidic & total sterols excretion in S.D. rats fed A A 
supplementation diets with three different dosages 
Diets Fecal acidic sterols Fecal neutral sterols Fecal total sterols 
(mg/day) (mg/day) (mg/day) 
B.C. 156±11.2' 461±19.7' 617 士 41.0" 
5 % A A 151 士3.50 A 4 4 4 ± 1 3 . 0 ' 5 9 5 ± 1 4 . 8 ' 
1 0 % A A 171 士 11.9 A 4 3 2 ± 8 . 9 3 ‘ 6 0 3 ± 3 5 . 4 ' 
2 0 % A A 125士5.80 B 3 4 3 ± 1 1 . 1 ^ 4 6 8 ± 3 8 . 8 ^ 
Data are expressed as mean 士 SE (n=8). 
Values in the same column with different superscripts (a, b) are significantly different 
between groups (ANOVA, Tukey, P<0.05). 
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Similar to that of mushroom screening investigation (3.1.4), there was no 
significant difference in fecal neutral sterol excretion between the AA 
supplementation groups and the control group except a significantly lower result was 
found in the 20% AA group. Moreover, there was no dose-response correlation 
between AA supplemented and fecal total sterol (both neutral and acidic sterols) 
excretion. Similar results were reported by Lee et al (1999), who also found a lower 
serum and hepatic lipid pool with a lower fecal sterol excretion, after feeding 
hesperetin (one major bioflavonoids in tangerine-peel extract) supplemented high 
cholesterol diet (1%, w/w) in rats. In that study, the control group excreted almost 
threefold neutral sterols when compared to the hesperetin diet group. Thus, the 
increase in the excretion of cholesterol was again not always a necessary mechanism 
of hypolipidemic effect. Another possible lipid-lowering mechanism might be due to 
the suppression of endogenous cholesterol synthesis (as refer to 3.1.4), or a lesser 
utilization of exogenous cholesterol (as refer to 3.1.4). Furthermore, in the present 
result, a large amount of lithocholic acid was found as the major component in the 
fecal acidic sterols of all diet groups. It is well known that there are three major bile 
acids present in bile of human: cholic acid 40%, chenodeoxycholic acid 40% and 
deoxycholic acid 20% (Hofmann, 1976), with a similar situation found in rats (Uchida 
et al., 2001)�However, the GLC profile of this study had lithocholic acid as the largest 
peak. It was probably because of the bacterial dehydroxylation of chenodeoxycholic 
acid, due to the action of enterobacterium in the rat's colon (Groh et al” 1993). This 
led to another hypothesis of the hypolipidemic effect of AA: The bacterial flora in the 
colon could ferment the dietary fiber of AA, producing SCFAs, especially propionate, 
which was believed to be an HMG-CoA reductase inhibitor (Wright et al., 1990). On 
the other hand, SCFAs could stimulate the large intestine to secrete more 
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enteroglucagon which was against the cholesterol synthesis as well (Goodlad et al., 
1989). Moreover, another practical issue had occurred during the derivatisation of 
fecal acidic sterols (2.2.5.3). After methylation of acidic sterols by adding methanol, 
dimethoxypropane and concentrated HCl, the mixture of fecal sample was left to 
stand overnight at room temperature. In fact, after this step, the solid sediment was 
formed which was made up of salts that were produced by the neutralization 
procedure in the above step. This large amount of useless solid would interfere the 
TMS derivatisation resulting a lesser yield of TMS-ether derivatives. Therefore, the 
mixture should be centrifuged to discard this sediment before the derivatisation step, 
which would greatly improved the efficiency of the fecal acidic sterols being 
converted to their TMS-ether derivatives and the efficiency to dry them by blowing of 
nitrogen gas in the next step. 
3.2.6 Summary (dose response study) 
In this section, the dose-dependent response of AA was under investigation. 
Different amounts of AA dry powder (w/w) (5%, 10% and 20%) were added in an 
isocaloric diet to study if there is a dose-dependent response correlation between the 
amount of AA supplementation in the diets and their lipid-lowering effect. 
Overall, the present results of serum and hepatic lipid profiles showed that there 
was not a clear dose response correlation between the amount (from 5% to 20%) of 
AA supplemented in a high cholesterol diet (2%, w/w) and the hypolipidemic effect. 
However, it seemed that the amount of 5% A A in the diet was sufficient to reduce the 
serum & hepatic TC level to a significant level, and further increase in AA % in the 
diet did not result in a significantly higher hypolipidemic activity in the rats. 
Moreover, a positive and statistically significant correlation was demonstrated 
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between percentage of AA supplementation in diets and HDL/TC ratio (R-0.987; 
P<0.001), as well as a negative and statistically significant correlation in Athero. 
Index (R=-0.976; P=0.004), which might show a dose response relation of AA and its 
anti-atherosclerosis effect. On the other hand, the amount of the fecal neutral, acidic, 
and total sterol excretion in all the AA dosage groups was not significantly higher 
than the control group, which suggested that the hypolipidemic effect of AA might be 
due to other possible mechanisms such as the suppression of the endogenous 
cholesterol synthesis, especially inhibiting the HMG-CoA reductase activity by 
SCFAs (fermented dietary fiber of AA by enterobacterium in the colon). 
3.3 Hypolipidemic effect of ethanol extract (E.E.) & water extract 
(W.E.) from A A in hyperlipidemic S.D. rats 
Total 252g dried AA powders were used in the extraction based on the 
equivalent amount in a 5% AA supplemented diet consumed by twenty-four rats, with 
a daily intake of 30g each for 3 weeks. Then the serum lipid profiles, hepatic lipid 
profiles and fecal neutral & acidic sterols of the animals were analyzed as before. 
3.3.1 Extraction yield 
The yield of the ethanol and hot water extraction of AA mushroom was 
10.36%, and 39.21%, respectively. The amount of daily oral administration of E.E. 
and W.E. was 155.3 mg and 588.1 mg, respectively. 
3.3.2 Body weight & food intake 
The daily food intake of ethanol extract group was significantly higher than 
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that of B.C. group by 7.8% (P<0.05), but the rats' body weight gain and final body 
weight were not significantly different from those of the B.C. group [increased by 
7.66% (P-0.134) and 4.31% (P=0.114) respectively] (Table 3-8). 
Table 3-8 
The food intake and body weight gain of S.D. rats fed ethanol extract 
and hot water extract from A A mushroom 
Food intake Initial body Final body Body weight 
Diet 
(g/day/rat) weight (g) weight (g) gain (g/day) 
B.C. 25.6±0.69 ^ 161±1.44^ ^ 3 0 1 ± 6 . 4 1 ^ 6.66±0.25 ^ 
W.E. 25.1 士0.57 a 162±0.88 ^ 299士4.53 a 6.54士0.19 a 
E . E . 2 7 . 6 ± 0 . 3 5 ^ 1 6 4 ± 1 . 0 5 ^ 314士4.41 A 7.17士0.20 A 
Data are expressed as mean 士 SE (n=8). 
Values in the same column with different superscripts (a, b) are significantly different 
between groups. (ANOVA, Tukey, P<0.05) 
3.3.3 Effect of A A extract supplementation on serum lipid profiles 
3.3.3.1 Effect of A A extract supplementation on serum T C level 
Twenty-four male S.D. rats were mixed randomly in three groups with eight 
each. The mean value of baseline serum TC level was 78.4 士3.51 (SE) (mg/dL). After 
3 weeks feeding, fasting serum TC level of the B.C group was increased by 5.34% 
compared to the Baseline level, while that of the W.E. and E.E. groups was decreased 
by 13.9% and 3.55%, respectively. However, there was no statistical significant 
difference between W.E. (P-0.170), E.E. (P-0.602) and the control group (Figure 3-
19). 
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Figure 3-19 
Serum T C level in S.D. rats fed A A extract supplementation 
diets 
3.3.3.2 Effect of A A extract supplementation on serum T G level 
The fasting serum TG level was similar in all diet groups and only a slight 
reduction in the W.E. group by 5.03% compared to control group was observed 
(Figure3-20). 
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Figure 3-20 
Serum T G level in S.D. rats fed AA extract supplementation diets 
3.3.3.3 Effect of AA extract supplementation on serum H D L level 
In line with the reduction in serum TC level observed in 3.3.3.1, the serum 
HDL level of the W.E. and E.E. groups were also slightly decreased though not 
significantly by 14.1% (P=0.191) and 3.00%, respectively as compared to the B.C. 
group (Figure 3-21 A). 
The HDL/TC ratio was slightly raised though also not significantly, in the W.E. 
(3.64%) and E.E. groups (9.10%) compared to B.C. group (Figure 3-21B). 
Accordingly, the Athero. Index was reduced though not significantly in the 
W.E. (15.5%), E.E. groups (14.4%) as compared to the B.C. group (Figure 3-21C). 
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Figure 3-21 
Serum H D L cholesterol level (3-21A)，HDL/TC ratio (3-21B) and 
Athero. Index (3-21C) in S.D. rats fed A A extract supplementation diets 
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3.3.4 Effect of A A extract supplementation on hepatic lipid profiles 
There was no significant difference in the hepatic total lipid and total 
cholesterol levels between the AA extract supplementation diet groups and the B.C. 
group (Figure 3-22; 3-23), only a slight reduction in the TL and TC level of W.E. 
group (1.86% and 3.22%, respectively) compared to the B.C. group was observed 
(Figure 3-22; 3-23). 
3.3.5 Effect of A A extract supplementation on fecal neutral & acidic 
sterols excretion 
Three neutral sterols coprostanol, cholesterol and campesterol were observed in 
the GLC analysis of the rat fecal samples, with cholesterol as the dominant 
component ( ^ 97%) (data not shown). 
The total fecal neutral sterol output in the W.E. and E.E. groups were similar 
to that of the B.C. group, except a significant enhancement of coprostanol excretion 
was observed in W.E. group as compared to B.C. group (Table 3-9). Besides, there 
was no significant difference in the fecal acidic sterol excretion between the two AA 
extract groups and the control group (Table 3-10). 
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Figure 3-22 
Hepatic total lipid level (mg/g liver) in S.D. rats fed A A extract 
supplementation diets 
170 r 
160 h T T 
(D i T 
T ~ ~ 
：^ 150「 _ _ 
、 
旦 140卜 





1 0 0 ‘ 丨 1 
B.C. W.E. E.E. 
(Values are means 士SE, n=8.) 
Figure 3-23 
Hepatic total cholesterol level (mg/g liver) in S.D. rats fed A A 
extract supplementation diets 
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Table 3-9 
The fecal neutral sterol excretion in S.D. rats fed A A extract 
supplementation diets 
Fecal neutral sterols (mg/day) 
Diet 
Coprostanol Cholesterol Campesterol Total 
" " ” B ! C 6 . 5 7 ± 0 . 8 5 ^ 4 0 1 士 10.3 A 4.88士0.45 ^ 412士 12.6 A 
W.E. 8.26士0.97 B 395士6.78 A 4.96士0.23 A 4 0 8 ± 8 . 0 0 ^ 
E.E. 7 . 0 1 士 0 . 6 1 a，b 388士 12.1 ^ 4 . 6 9 ± 0 . 2 9 ^ 400士 13.8 ^  
Data are expressed as mean 士 SE (n=8). 
Values in the same column with different superscripts (a, b) are significantly different 
between groups (ANOVA, Tukey, P<0.05). 
Table 3-10 
The fecal acidic & total sterol excretion in S.D. rats fed A A 
supplementation diets 
Fecal acidic Fecal neutral Fecal total 
Diet 
sterols (mg/day) sterols (mg/day) sterols (mg/day) 
B . C . 143±9.24 ^ 412士 12.6 A 5 5 5 ± 3 0 . 4 ^ 
W.E. 141 士8.50 a 408±8.00 ^ 549土 15.8 a 
E.E. 129±lL3a 400±13.8a 528d=36.7 ^ 
Data are expressed as mean 士 SE (n=8). 
3.3.6 Discussion (active fraction extract study) 
In these experiments, fractionation of active hypolipidemic components in 
AA into ethanol extract (E.E) and hot water extract (W.E.) was attempted. 
The extraction yield of hot water, which probably contained more protein and 
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saccharides, was threefold more than that of ethanol (Bobek et al., 1993). The 
ethanolic extract should contain polar components with small molecular weight, like 
two active hypolipidemic compounds, grifolin (2-trans, trans-famesyl-5-
methylresorcinol) and neogrifolin (4-trans, trans-famesul-5-methylresorcinol), which 
were obtained from the ethyl acetate-soluble fraction of 80% ethanol extract of 
ningyotake {Polyporus confluens) mushroom (Sugiyama et al., 1992). About the food 
intake and final body weight, addition of the E.E seemed to stimulate the appetite of 
the rats and the growth of the animals was faster in the E.E. group than that in the W.E. 
and the B.C. groups. Furthermore, the serum TC level of the W.E. group and E.E. 
group was decreased as compared to the control group though without a statistical 
significant. Moreover, in the serum TG and HDL cholesterol level, similar 
insignificant reduction had occurred in the W.E. group. And the HDL/TC ratio of the 
E.E. and W.E. groups were both enhanced as compared to B.C. group, which 
accounted for a reduction in the Athero. Index of the W.E. and E.E. group. On the 
other hand, the hepatic TL and TC levels of the W.E. group were slightly lower than 
that of B.C. group with almost no change in the E.E. group. Finally, whether in the 
fecal neutral or acidic sterols output, there was no significant difference among the 
W.E. group, E.E. group and the control group. 
Based on the above data, three key conclusions could be drawn: 
Firstly, although the hypolipidemic effect caused by the oral administration of the 
W.E. of A A, was not statistically significant in both the serum and hepatic lipid 
profiles, the trend of lipid reduction in such a short period (3 weeks) was apparent. 
Similarly, the hot water extract of hatakeshimeji {Lyophyllum decastes Sing.) 
mushroom was found to have a significant effect to lower serum TC levels of rats 
when added at a level of 10% to a high cholesterol diet (Ukawa et aL, 2002). It was 
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anticipated that the lipid-lowering effects of W.E. observed in the present experiments 
would have been more profound if the feeding period could last longer, like the six 
weeks in vivo study to confirm the hypolipidemic effect of water extract of P. 
ostreatus (Bobek et al., 1993), or even twelve weeks to determine the same effect of 
ethanolic extract of the same mushroom (Bobek, et al., 1996). 
Secondly, as the total extraction yield of W.E. and E.E. in this research was only 
50%, there were two possible implications: On one hand, if the active hypolipidemic 
fraction had similar solubility and polar character in the hot water extraction or 
ethanolic extraction, it may be distributed to both of them due to the similar chemical 
characters (like polar character) between water and ethanol, which will lead to a 
"diluted" hypolipidemic effect of the active fraction. On the other hand, after the 
ethanol and water extraction, the active lipid-lowering substance might still remain in 
the solid residue. 
Thirdly, some proven hypolipidemic agents present in other mushrooms, like 
eritadenine in L. edodes (Sugiyama and Yamakawa, 1996) and lovastatin in P. 
ostreatus (Cimerman and Cimerman, 1995), might play a key role in AA as well. The 
presence of these or similar compounds could be confirmed by using other specific 
chemical isolation methods (Chibata et al., 1969). 
All in all, the AA hot water extraction showed a potential hypolipidemic 
effect even in a short period of administration. Some long-term feeding studies and 
different solvent extraction scheme might be considered for future investigation. 
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3.4 Long term evaluation of the hypolipidemic effect of A A 
supplementation in normolipic S.D. rats 
The last section of this research project involved a long term (12 weeks) 
feeding of S.D. rats with the 5% (w/w) AA supplementation in a normolipic diet for 
the investigation of the hypolipidemic mechanisms in terms of cholesterol regulatory 
enzymes. 
3.4.1 Body weight & food intake 
The average daily food intake of rats fed AA diet was significantly lower 
than that of control group by 13.7% (PO.OOl) (Table 3-11); However, the body 
weight gain and the final body weight of the rats in the AA diet group increased 
significantly by 14.0% and 10.3% compared with the control group. These results 
showed that the AA mushroom had desirable nutritional value in rats when fed for a 
long period (Table 3-11). 
Table 3-11 
The food intake and body weight results of S.D. rats in the long term 
evaluation of A A supplementation diets 
Food intake Initial body Final body Body weight 
Diet 
(g/day/rat) weight (g) weight (g) gain (g/day) 
R C 2 9 . 2 ± 0 . 5 4 134±1.13 505±15.4 4.42士 0.18 
* 氺 氺 氺 氺 
AA 25.2±0.55 134±1.74 557±15.0 5.04±0.18 
Data are expressed as mean 士 SE (n=7). 
(Student t-test, P<0.05; ***: PO.OOl.) 
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3.4.2 Effect of long term A A supplementation on serum lipid profiles 
3.4.2.1 Effect of long term A A supplementation on serum T C level 
The mean value of the baseline serum TC level of rats was 84.66 士 2.60 (SE) 
(mg/dL) at the beginning of the long-term experiment. During the three months 
feeding period, there was a continuous decrease effect in serum TC level of the rats in 
AA diet group compared to the control group, though the reduction was not 
significant. Specifically, the % decrease of the V\ and months was 6.2, 3.0, and 
6.2, respectively. (Figure 3-24). 
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Figure 3-24 
Serum T C level in S.D. rats fed A A supplementation diet during 
three months experiment 
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3.4.2.2 Effect of long term A A supplementation on serum T G level 
The mean value of the baseline semm TG level of rats was 29.16 士 4.77 (SE) 
(mg/dL) at the beginning of the long-term experiment. Then the semm TG level in the 
rat grew up to a peak value of 84.05 士 8.26 (SE) (mg/dL) (B.C. group) and 88.53 士 
6.30 (SE) (mg/dL) (AA group) after two months feeding. However, the increase rate 
of serum TG level in AA diet group was slightly faster than the control group during 
the first and second months. Moreover, the variation of the semm TG level of both 
diet groups was similar and without statistically significant difference (Figure 3-25). 
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Figure 3-25 
Serum T G level in S.D. rats fed A A supplementation diets during 
three months experiment 
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3.4.2.3 Effect of long term A A supplementation on serum H D L level 
The results of fasting serum HDL, HDL/TC ratio and Athero. Index were all 
similar in the AA group and the control group without any significant difference 
(Table 3-12). 
Table 3-12 
The serum H D L , HDL/TC ratio and Athero. Index of S.D. rats in 
long term evaluation of A A supplementation diets 
Diets HDL (mg/dL) HDL/TC Athero. Index 
— ~ B ^ 69.9±3.98 0.78士0.02 0.30士 0.04 
AA 67.3±5.62 0.79士 0.01 0.27 士 0.01 
Data are expressed as mean 土 SE (n=7). 
3.4.3 Effect of long term A A supplementation on hepatic lipid profiles 
The hepatic total lipid level (mg/g liver) of the AA supplemented group was 
reduced by 10.1% (P二0.210) compared to that of control group. (Figure 3-26) 
Similarly, the hepatic total cholesterol level (mg/g liver) of the AA 
supplementation group was also decreased by 25.3% (P二0.125) compared to the 
control group (Figure 3-27). 
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Figure 3-26 
Hepatic total lipid level of S.D. rats in long term experiment 
of A A supplemented diet 
28 - --
？ 241 r ^ 
!：[ 1 rl 
I 4 - J I 
Q L M 丨 ' M , 
B.C. AA 
(Values are means 士SE, n=7.) 
Figure 3-27 
Hepatic total cholesterol level of S.D. rats in long term 
experiment of A A supplemented diet 
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3.4.4 Effect of long term A A supplementation on fecal neutral & 
acidic sterols excretion 
The fecal samples of the last four days during the 3 months feeding period 
were collected, pooled and analyzed by GLC. It could be seen that AA 
supplementation greatly increased the fecal sterol excretion (Table 3-13). In specific, 
compared to control group, there was a large increase in coprostanol (23.8%) 
(P=0.681), cholesterol (61.8%) (P=0.019), campesterol (18.2%) (P0.057), neutral 
sterol excretion subtotal (27.5%) (P=0.009), and to a lesser extent in acidic sterol 
excretion (3.5%) (P=0.477). The overall amount of total sterols in AA diet group was 
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3.4.5 Effect of long term A A supplementation on key enzymes of 
hepatic cholesterol metabolism 一 H M G - C o A reductase and C Y P 7 A 
From the above data, long term feeding of AA could reduce the serum lipid 
profiles, hepatic lipid profiles and increase the fecal total sterol excretion in rats. In 
order to elucidate the hypolipidemic mechanisms of AA especially its effect to the 
endogenous cholesterol homeostasis, the activity of HMG-CoA reductase and 
cholesterol 7a-hydroxylase (CYP7A) in the rat's liver were analyzed. 
3.4.5.1 Quantitation of hepatic microsomal protein 
By calibration of a standard bovine serum albumin (BSA) curve of Lowry 
protein assay (Figure 3-28), the concentration of hepatic microsomal protein of the 
S.D. rat's liver in the AA and B.C. group, was found to be 5.69 士 0.24 and 5.70 士 0.21, 
respectively (mg/ml). 
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Figure 3-28 
Standard curve of Lowry protein assay (BSA) by absorbance at 725nm 
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3.4.5.2 Effect of long term A A supplementation on H M G - C o A 
reductase activity in S.D. rats 
The hepatic HMG-CoA reductase activity in the AA diet group greatly 
decreased by 37.6% (P=0.059) compared to the control group, implying that the AA 
supplementation could effectively suppress the cholesterol biosynthesis in the rats' 
liver (Figure 3-29). 
3.4.5.3 Effect of long term A A supplementation on C Y P 7 A activity in 
S.D. rats 
The CYP7A activity in the AA group was significantly increased to more than 
two-fold of that in B.C. group (Figure 3-30), suggesting that the AA supplementation 
could significantly accelerate the cholesterol degradation in the liver after a long term 
feeding period. 
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Figure 3-29 
Effect of hepatic H M G - C o A reductase activity in S.D. rats of long 
term experiment by A A supplementation diet 
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Figure 3-30 
Effect of hepatic CYP7A activity in S.D. rats of long term experiment 
by A A supplementation diet 
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3.4.7 Discussion (Long term study) 
In this study, the long- term hypolipidemic effect of AA supplementation of 
normolipic rats, as well as the exploration about the lipid-lowering mechanism in 
terms of two key regulatory enzymes in cholesterol metabolism were investigated. 
Firstly, the overall mean value of daily food intake of rats in the AA diet group 
was significantly lower than that of the control group. On the contrary, both of the rate 
of body weight gain and the final body weight of the AA diet group increased when 
compared to the B.C. group. This indicated that consumption of a low dose (5%) of 
AA supplementation diet with low cholesterol could result in a faster growing rate in 
the rats than a control diet. These results were somewhat unexpected because of the 
poorer protein digestibility of AA than that of casein in the control group (Wong, 
2002). One possible explanation may be due to the regulation of glucose metabolism. 
For instant, an acidic polysaccharide (TAP) from the fruiting body of Tremella 
aurantia was demonstrated to have the remarkable hypolipidemic effect, as well as 
hypoglycemic activity, which increased the activities of glucokinase and hexokinase 
participating in the uptake of glucose in the liver, and decreased the activity of 
glucose-6-phosphatase responsible for removal of glucose from the liver, all of which 
might have a positive effect on growth (Kiho et al., 2000). All in all, both in vitro and 
in vivo evaluation of the nutritional value of AA would be worthy in future. 
Secondly, the present data showed a continuous lowering effect on the fasting 
serum TC level of the AA diet group than the control group throughout the whole 
experiment period. While in serum TG and HDL level, there was no significant 
difference between the two diet groups. Similar results had been reported by Bebek 
and Ozdin (1994b) on the investigation of hypolipidemic effect of oyster mushroom 
{Pleurotus ostreatus) fed in chow-induced hyperlipidemic rats. They found that the 
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serum VLDL and LDL cholesterol levels contributed equally in the reduction of 
serum TC level by 30%, while the HDL cholesterol concentration significantly 
increased by more than 30%, which suggested that a shift of serum VLDL & LDL 
rich lipoprotein profiles to a HDL rich one might likely account for the hypolipidemic 
and anti-atherosclerotic effect of the mushroom (Bobek and Ozdin, 1994b). This is 
because serum LDL cholesterol level is well-known as a single, independent risk 
factor for the development of CHD (Heyden et al., 1971; Hill and Wynder, 1976)， 
while plasma concentrations of HDL-cholesterol level is inversely correlated with the 
incidence of CHD (Miller et al； 1975; Gordon et al., 1989). Therefore, the present 
data of AA mushroom—a decrease in serum TC level as well as no influence in serum 
HDL level一indicated that AA might also predominantly lower the serum VLDL and 
LDL cholesterol concentrations similar to that in Pleurotus ostreatus (Bobek and 
Ozdin, 1994b). 
Thirdly, the hepatic TL and TC levels were all decreased in the AA 
supplementation diet, showing that hepatic biosynthesis of cholesterol might be 
suppressed. It could be due to the reduction in the activity of the HMG-CoA reductase, 
inhibiting the endogenous cholesterol biosynthesis (Bobek et al., 1995a). This 
hypothesis had also been confirmed by the fact that the activity of this enzyme in the 
AA diet group was reduced by 37.6% compared to that of control group. Furthermore, 
another possible hypocholesterolemic mechanism of AA was the stimulation of the 
activity of CYP7A, a key enzyme to catalyze the conversion of cholesterol to bile 
acids, which were secreted into the intestine and out of the body via feces (Bobek et 
al., 1994c). The present results were consistent with this hypothesis by showing a 
significantly higher CYP7A activity in the AA diet group than that of control group. 
Fourthly, concerning the fecal neutral sterol excretion, the present data of the 
127 
__ Chapter Three: Results and discussion 
AA diet group were significantly higher than that of the control group, which 
confirmed another well-established possible mechanism to lower the body cholesterol 
pool, which was proposed as the hypolipidemic effects of dietary fiber (Cheung 1996a, 
1996b, 1998; Fukushima et al., 2001). The fecal neutral sterols are capable of 
reducing the intestinal cholesterol absorption, by decreasing the capacity of micelles 
to bind cholesterol during absorption (Heineman et al., 1991). However, this result 
was in contrast with the data of the short term feeding of AA mushroom 
supplemented in the high cholesterol diet. In a hypercholesterolemic diet, no 
significant difference of fecal total sterol excretion existed between the AA mushroom 
diet group and control group (the possible explanations refer to 3.1.4; 3.2.5). This 
suggested that there might be a shift in the hypolipidemic mechanisms of AA 
mushroom between a short term (4 wk) feeding experiment under 
hypercholesterolemic condition and a long term (12 wk) feeding study under 
normolipic condition. 
On the other hand, the fecal acidic sterol excretion of the AA diet group was 
slightly higher than that of the control group. This might be due to a combined effect 
of two hepatic enzymes: HMG-CoA reductase and CYP7A. On one hand, the activity 
of HMG-CoA reductase was inhibited, which might result in a lower synthetic rate to 
the endogenous cholesterol leading to a lower cholesterol pool of the AA diet group 
than that of the control group. On the other hand, CYP7A activity was upregulated, 
causing a higher conversion rate of cholesterol to bile acids. This combined effect 
might be used to explain the present results that the acidic sterol excretion of a lower 
total cholesterol pool with a higher cholesterol degradation rate (AA group) was even 
slightly higher than that of a higher cholesterol pool with a lower catalyzed 
conversion rate (B.C. group). 
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All in all, in a long period feeding on a normolipic diet to rats, AA 
supplementation could continuously lower the cholesterol accumulation in blood and 
liver, possibly by a multiple hypolipidemic mechanisms, which were likely to be 
different from that of feeding under hypercholesterolemic condition for shorter period. 
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Chapter four: conclusion and future perspectives 
Mushrooms have long been consumed as a delicious food in both the eastern and 
western societies (Chang and Miles, 1989). In recent years, some of them have been 
demonstrated to have hypolipidemic effect and other pharmacological values 
(Cimerman, 1999). Eleven lesser-known edible and medicinal mushrooms were 
chosen in in vivo test to determine their potential hypolipidemic effect. Among them, 
two Pleurotus mushrooms (PEVN, PE) and a lesser-known mushroom Agrocybe 
aegerita (Brig) Sing (AA) showed substantial serum TC lowering capacity without 
significantly influencing the serum HDL-cholesterol level. This indicated likely that 
the LDL-cholesterol was predominantly decreased as a result of the 
hypocholesterolemic effect of these mushrooms. Furthermore, these mushrooms 
greatly inhibited the lipid accumulation in the rat's liver by decreasing the hepatic TL 
and TC levels, as well as not showing a trend of increase in fecal neutral & acidic 
sterol excretion in chow-induced hypercholesterolemic rats. 
In the dose-dependant response study, different amounts (5%, 10% and 20%) of 
AA supplementation were used to see if an increased amount of AA could further 
improve its hypocholesterolemic effect. The present results showed that all three 
dosages of AA in the diets could significantly reduce the semm and hepatic TC levels, 
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but without significant difference found among them. However, a significant, positive 
correlation was observed between the amount of AA supplemented in the diets and 
the HDL/TC ratio. Accordingly, another significant, negative correlation was 
observed between the amount of AA supplemented in the diets and the Athero. Index 
as well. These observations suggested that an increase in the percentage of AA 
supplementation in the diets might enhance the anti- atherosclerotic effect. 
For the study of the active components in AA, pure ethanol extraction and hot 
water extraction of AA were orally administered to rats fed a hypercholesterolemic 
diet. Although the hypolipidemic effect of these two extracts was not obvious after 
three weeks, W.E. showed an apparent trend of decrease in the serum and hepatic TC 
levels as compared to E.E.. This indicated that the hot water extraction of AA might 
be a worthy target to seek the active lipid-lowering components in future studies. 
In the above three studies, AA supplementation did not show an increase trend 
on the fecal neutral & acidic sterol excretion. But in the fecal acidic sterols, the 
predominant component was a secondary bile acidlithocholic acid, suggesting that 
an increase in the activity of enterobacterium, which might ferment the dietary fiber 
component of AA to produce some SCFAs, suppressing the cholesterol biosynthesis 
by inhibiting the activity of HMG-CoA reductase. Thus, further intensive 
investigations still need to elucidate the detailed hypolipidemic mechanisms of AA 
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under a hypercholesterolemic condition. 
In the long-term study, 5% A A supplementation showed a constant lowering 
effect on serum & hepatic TC levels in normolipic rats. However, similar to the 
previous dose-response and active component studies, the serum TG level of AA diet 
group was fluctuated but without a significant reduction as compared to the control 
group. Furthermore, the effect of AA supplemented diet on the activity of HMG-CoA 
reductase一the rate limiting enzyme of endogenous cholesterol synthesis 
procedure一was measured by [i4-C] labeled method. The present results confirmed 
that AA indeed suppressed this enzyme activity by 37.6% as compared to the control 
group. Therefore, the de novo cholesterol synthesis might be decreased in the AA diet 
group. Moreover, the influence of AA on the activity of CYP7A~the important 
enzyme of cholesterol degradation——was measured as well. The result indicated that 
AA supplemented diet significantly up regulated this enzyme activity by more than 
twofolds compared to the control group, suggesting that the cholesterol catabolism 
was greatly accelerated by AA supplementation. Furthermore, the fecal neutral sterol 
excretion in the AA diet group was significantly higher than that in the control group 
during the long term feeding of AA supplemented diet, which should be another 
possibility to reduce the total body cholesterol pool in the animals. 
Overall, AA showed a marked hypolipidemic function in reducing serum and 
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hepatic TC levels as compared to the control group, both in a hypercholesterolemic 
diet and a normolipic diet. The mechanisms in the former still need to be clarified, 
while the mechanisms in the normolipic rats are most likely to be associated with the 
suppression of de novo cholesterol synthesis by inhibiting hepatic HMG-CoA 
reductase activity, acceleration of the rate of cholesterol catabolism by stimulation of 
hepatic CYP7A activity, as well as the enhancement of fecal sterol excretion. It was 
suggested that the hypolipidemic mechanisms of AA might be multifarious and varied 
under different physiological conditions. All in all, AA could be a potential functional 
food to protect the body from hypercholesterolemia and atherosclerosis. 
AA is a newly cultivated edible mushroom, which belongs to the family of 
Bolbitiaceae (Mao, 2000). However, very few published data of this mushroom is 
available so far, especially its hypolipidemic effect. Further investigations are 
necessary to better understand this mushroom. Here are some suggestions about the 
future studies: 
1) Of the dose-dependent response study, since 5%, 10% and 20% AA 
supplementation showed similar hypolipidemic effect, a lower doses like 2.5% 
and 1% could be used in the future to find out the lowest effective hypolipidemic 
dosage; 
2) Of the active fraction investigation, more extraction solvents with different 
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polarity (such as 20%, 40% and 80% ethanol-water mixture) could be used to 
further fractionate the active hypolipidemic component(s) in AA (Bobek et al., 
1993). Moreover, the analysis of the solid residue after extraction should not be 
neglected since it still constituted about 50% of the total mushroom dry powder. 
Meanwhile, a longer feeding period of W.E. in a hypercholesterolemic diet, such 
as six weeks (Bobek et al., 1993) or even twelve weeks (Bobek et al” 1996), 
could be used to determine whether the lipid-lowering effect of AA would be 
persistent. Furthermore, concerning the difficulty in forming AA ethanolic 
extract-water emulsion which caused some losses of the extract due to remains 
left in the syringe needle during the procedure of oral administration, a better 
emulsifying medium can be found by using some cornstarch solutions in future 
work. Moreover, the determination of other well-known hypolipidemic agents, 
which were previously found in other mushrooms, such as eritadenine and 
lovastatin in AA could be done in order to find the active hypolipidemic 
ingredient(s). 
3) Concerning the elucidation of the hypolipidemic mechanisms, in vitro 
investigation such as in primary cultures of mouse fetal liver cells and in L cell 
(Kandutsch and Chen, 1974) and to see if AA contains HMG-CoA reductase 
inhibitor, is valuable. Furthermore, the activity of another important enzyme, 
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which catalyzes the intestinal cholesterol absorption and its esterification一 
acyl-CoA-cholesterol acyl transferase (ACAT) (EC 2.3.1.26) could be studied. 
Cholesterol is absorbed and internalized into the mucosal cell at free form, but it 
is esterified predominantly in lymph (Shiratori and Goodman, 1965). Therefore, 
inhibiting ACAT activity may be an alternative way to decrease the pool of serum 
cholesterol (Zhang et al., 2002a). 
4) An extensive nutritional evaluation of AA both in vitro and in vivo studies are 
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